KR102516717B1 - A cosmetic composition for improved skin having panthenol and niosome - Google Patents
A cosmetic composition for improved skin having panthenol and niosome Download PDFInfo
- Publication number
- KR102516717B1 KR102516717B1 KR1020220112171A KR20220112171A KR102516717B1 KR 102516717 B1 KR102516717 B1 KR 102516717B1 KR 1020220112171 A KR1020220112171 A KR 1020220112171A KR 20220112171 A KR20220112171 A KR 20220112171A KR 102516717 B1 KR102516717 B1 KR 102516717B1
- Authority
- KR
- South Korea
- Prior art keywords
- niosome
- panthenol
- skin
- active ingredients
- cosmetic composition
- Prior art date
Links
- 239000002353 niosome Substances 0.000 title claims abstract description 77
- SNPLKNRPJHDVJA-ZETCQYMHSA-N D-panthenol Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCCO SNPLKNRPJHDVJA-ZETCQYMHSA-N 0.000 title claims abstract description 52
- 239000000203 mixture Substances 0.000 title claims abstract description 48
- 229940101267 panthenol Drugs 0.000 title claims abstract description 47
- 235000020957 pantothenol Nutrition 0.000 title claims abstract description 47
- 239000011619 pantothenol Substances 0.000 title claims abstract description 47
- 239000002537 cosmetic Substances 0.000 title claims abstract description 27
- 230000001976 improved effect Effects 0.000 title description 3
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims abstract description 53
- 239000004480 active ingredient Substances 0.000 claims abstract description 38
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 claims abstract description 28
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims abstract description 26
- 229960000458 allantoin Drugs 0.000 claims abstract description 26
- 230000006872 improvement Effects 0.000 claims abstract description 18
- -1 foundation Substances 0.000 claims description 36
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 28
- 239000002736 nonionic surfactant Substances 0.000 claims description 17
- 235000012000 cholesterol Nutrition 0.000 claims description 14
- 239000002245 particle Substances 0.000 claims description 14
- 239000003381 stabilizer Substances 0.000 claims description 12
- 239000006210 lotion Substances 0.000 claims description 10
- 239000006071 cream Substances 0.000 claims description 8
- 239000003795 chemical substances by application Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 239000000839 emulsion Substances 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 239000000314 lubricant Substances 0.000 claims description 5
- 239000007957 coemulsifier Substances 0.000 claims description 4
- 239000002453 shampoo Substances 0.000 claims description 4
- 239000000344 soap Substances 0.000 claims description 4
- 239000000443 aerosol Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 230000000475 sunscreen effect Effects 0.000 claims description 3
- 239000000516 sunscreening agent Substances 0.000 claims description 3
- 239000000606 toothpaste Substances 0.000 claims description 3
- 229940034610 toothpaste Drugs 0.000 claims description 3
- 230000000694 effects Effects 0.000 abstract description 19
- 230000003020 moisturizing effect Effects 0.000 abstract description 12
- 230000035515 penetration Effects 0.000 abstract description 9
- 230000009471 action Effects 0.000 abstract description 7
- 239000013566 allergen Substances 0.000 abstract description 7
- 230000007794 irritation Effects 0.000 abstract description 7
- 210000003491 skin Anatomy 0.000 description 55
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 17
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 230000000052 comparative effect Effects 0.000 description 14
- 239000003995 emulsifying agent Substances 0.000 description 14
- 235000010445 lecithin Nutrition 0.000 description 14
- 239000000787 lecithin Substances 0.000 description 14
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 12
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 12
- 235000014113 dietary fatty acids Nutrition 0.000 description 12
- 239000000194 fatty acid Substances 0.000 description 12
- 229930195729 fatty acid Natural products 0.000 description 12
- 229940067606 lecithin Drugs 0.000 description 12
- 239000002502 liposome Substances 0.000 description 12
- 239000003921 oil Substances 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 239000011734 sodium Substances 0.000 description 10
- 229910052708 sodium Inorganic materials 0.000 description 10
- 229940083542 sodium Drugs 0.000 description 10
- 235000015424 sodium Nutrition 0.000 description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- 230000001965 increasing effect Effects 0.000 description 9
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 229940008099 dimethicone Drugs 0.000 description 8
- 239000004205 dimethyl polysiloxane Substances 0.000 description 8
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 8
- 235000011187 glycerol Nutrition 0.000 description 8
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 8
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 8
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 230000003110 anti-inflammatory effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 239000004094 surface-active agent Substances 0.000 description 7
- 229940114079 arachidonic acid Drugs 0.000 description 6
- 235000021342 arachidonic acid Nutrition 0.000 description 6
- 210000005069 ears Anatomy 0.000 description 6
- 150000004665 fatty acids Chemical class 0.000 description 6
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 6
- 230000005764 inhibitory process Effects 0.000 description 6
- 150000002632 lipids Chemical class 0.000 description 6
- 229960004063 propylene glycol Drugs 0.000 description 6
- 235000013772 propylene glycol Nutrition 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- 235000010469 Glycine max Nutrition 0.000 description 5
- 206010061218 Inflammation Diseases 0.000 description 5
- 239000004359 castor oil Substances 0.000 description 5
- 235000019438 castor oil Nutrition 0.000 description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 5
- 230000004054 inflammatory process Effects 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 239000007908 nanoemulsion Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 235000000346 sugar Nutrition 0.000 description 5
- 235000004866 D-panthenol Nutrition 0.000 description 4
- 239000011703 D-panthenol Substances 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 244000068988 Glycine max Species 0.000 description 4
- 239000004166 Lanolin Substances 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- 239000002202 Polyethylene glycol Substances 0.000 description 4
- 208000003251 Pruritus Diseases 0.000 description 4
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 4
- 244000044822 Simmondsia californica Species 0.000 description 4
- 235000004433 Simmondsia californica Nutrition 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 229920002125 Sokalan® Polymers 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 229960000541 cetyl alcohol Drugs 0.000 description 4
- 238000011156 evaluation Methods 0.000 description 4
- 150000002191 fatty alcohols Chemical class 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 229960000905 indomethacin Drugs 0.000 description 4
- 235000019388 lanolin Nutrition 0.000 description 4
- 229940039717 lanolin Drugs 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 210000004379 membrane Anatomy 0.000 description 4
- 238000005191 phase separation Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 239000008107 starch Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- HLZKNKRTKFSKGZ-UHFFFAOYSA-N tetradecan-1-ol Chemical compound CCCCCCCCCCCCCCO HLZKNKRTKFSKGZ-UHFFFAOYSA-N 0.000 description 4
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 description 3
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 description 3
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- GHOKWGTUZJEAQD-UHFFFAOYSA-N Chick antidermatitis factor Natural products OCC(C)(C)C(O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-UHFFFAOYSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 206010040880 Skin irritation Diseases 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 description 3
- 239000008346 aqueous phase Substances 0.000 description 3
- 201000008937 atopic dermatitis Diseases 0.000 description 3
- 229960003237 betaine Drugs 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 229940036350 bisabolol Drugs 0.000 description 3
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 3
- 229960003949 dexpanthenol Drugs 0.000 description 3
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- 239000012188 paraffin wax Substances 0.000 description 3
- 229920005862 polyol Polymers 0.000 description 3
- 150000003077 polyols Chemical class 0.000 description 3
- 229920001296 polysiloxane Polymers 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000009759 skin aging Effects 0.000 description 3
- 210000004927 skin cell Anatomy 0.000 description 3
- 230000036556 skin irritation Effects 0.000 description 3
- 231100000475 skin irritation Toxicity 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 150000003431 steroids Chemical class 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 150000008163 sugars Chemical class 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 235000010384 tocopherol Nutrition 0.000 description 3
- 239000011732 tocopherol Substances 0.000 description 3
- 229960001295 tocopherol Drugs 0.000 description 3
- 229930003799 tocopherol Natural products 0.000 description 3
- 230000036572 transepidermal water loss Effects 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 2
- GHOKWGTUZJEAQD-ZETCQYMHSA-N (D)-(+)-Pantothenic acid Chemical compound OCC(C)(C)[C@@H](O)C(=O)NCCC(O)=O GHOKWGTUZJEAQD-ZETCQYMHSA-N 0.000 description 2
- BANXPJUEBPWEOT-UHFFFAOYSA-N 2-methyl-Pentadecane Chemical compound CCCCCCCCCCCCCC(C)C BANXPJUEBPWEOT-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- 208000010201 Exanthema Diseases 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 239000000232 Lipid Bilayer Substances 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- 229930195725 Mannitol Natural products 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010030113 Oedema Diseases 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- ZTHYODDOHIVTJV-UHFFFAOYSA-N Propyl gallate Chemical compound CCCOC(=O)C1=CC(O)=C(O)C(O)=C1 ZTHYODDOHIVTJV-UHFFFAOYSA-N 0.000 description 2
- 229920002385 Sodium hyaluronate Polymers 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- 235000021307 Triticum Nutrition 0.000 description 2
- 244000098338 Triticum aestivum Species 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 229930003571 Vitamin B5 Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- WNLRTRBMVRJNCN-UHFFFAOYSA-N adipic acid Chemical compound OC(=O)CCCCC(O)=O WNLRTRBMVRJNCN-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 2
- 230000003266 anti-allergic effect Effects 0.000 description 2
- 239000002260 anti-inflammatory agent Substances 0.000 description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 230000004888 barrier function Effects 0.000 description 2
- 235000013871 bee wax Nutrition 0.000 description 2
- 239000012166 beeswax Substances 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 2
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 2
- 229960002079 calcium pantothenate Drugs 0.000 description 2
- 229960001631 carbomer Drugs 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 229940081733 cetearyl alcohol Drugs 0.000 description 2
- 150000001841 cholesterols Chemical class 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 239000000428 dust Substances 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 2
- 201000005884 exanthem Diseases 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- HHLFWLYXYJOTON-UHFFFAOYSA-N glyoxylic acid Chemical compound OC(=O)C=O HHLFWLYXYJOTON-UHFFFAOYSA-N 0.000 description 2
- 239000003906 humectant Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000594 mannitol Substances 0.000 description 2
- 235000010355 mannitol Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229940043348 myristyl alcohol Drugs 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- BARWIPMJPCRCTP-UHFFFAOYSA-N oleic acid oleyl ester Natural products CCCCCCCCC=CCCCCCCCCOC(=O)CCCCCCCC=CCCCCCCCC BARWIPMJPCRCTP-UHFFFAOYSA-N 0.000 description 2
- BARWIPMJPCRCTP-CLFAGFIQSA-N oleyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC BARWIPMJPCRCTP-CLFAGFIQSA-N 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- CGIHFIDULQUVJG-UHFFFAOYSA-N phytantriol Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)(O)C(O)CO CGIHFIDULQUVJG-UHFFFAOYSA-N 0.000 description 2
- CGIHFIDULQUVJG-VNTMZGSJSA-N phytantriol Natural products CC(C)CCC[C@H](C)CCC[C@H](C)CCC[C@@](C)(O)[C@H](O)CO CGIHFIDULQUVJG-VNTMZGSJSA-N 0.000 description 2
- 239000000419 plant extract Substances 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 206010037844 rash Diseases 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 235000019172 retinyl palmitate Nutrition 0.000 description 2
- 229940108325 retinyl palmitate Drugs 0.000 description 2
- 239000011769 retinyl palmitate Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 230000008591 skin barrier function Effects 0.000 description 2
- 231100000245 skin permeability Toxicity 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229940010747 sodium hyaluronate Drugs 0.000 description 2
- 239000001540 sodium lactate Substances 0.000 description 2
- 229940005581 sodium lactate Drugs 0.000 description 2
- 235000011088 sodium lactate Nutrition 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 150000005846 sugar alcohols Polymers 0.000 description 2
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 235000009492 vitamin B5 Nutrition 0.000 description 2
- 239000011675 vitamin B5 Substances 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 description 1
- BQPPJGMMIYJVBR-UHFFFAOYSA-N (10S)-3c-Acetoxy-4.4.10r.13c.14t-pentamethyl-17c-((R)-1.5-dimethyl-hexen-(4)-yl)-(5tH)-Delta8-tetradecahydro-1H-cyclopenta[a]phenanthren Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C BQPPJGMMIYJVBR-UHFFFAOYSA-N 0.000 description 1
- CRDAMVZIKSXKFV-FBXUGWQNSA-N (2-cis,6-cis)-farnesol Chemical compound CC(C)=CCC\C(C)=C/CC\C(C)=C/CO CRDAMVZIKSXKFV-FBXUGWQNSA-N 0.000 description 1
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 description 1
- RQOCXCFLRBRBCS-UHFFFAOYSA-N (22E)-cholesta-5,7,22-trien-3beta-ol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CCC(C)C)CCC33)C)C3=CC=C21 RQOCXCFLRBRBCS-UHFFFAOYSA-N 0.000 description 1
- 239000000260 (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-ol Substances 0.000 description 1
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MRAMPOPITCOOIN-VIFPVBQESA-N (2r)-n-(3-ethoxypropyl)-2,4-dihydroxy-3,3-dimethylbutanamide Chemical compound CCOCCCNC(=O)[C@H](O)C(C)(C)CO MRAMPOPITCOOIN-VIFPVBQESA-N 0.000 description 1
- CUNWUEBNSZSNRX-RKGWDQTMSA-N (2r,3r,4r,5s)-hexane-1,2,3,4,5,6-hexol;(z)-octadec-9-enoic acid Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O.CCCCCCCC\C=C/CCCCCCCC(O)=O CUNWUEBNSZSNRX-RKGWDQTMSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- WQKLGQXWHKQTPO-UXRZSMILSA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-methoxyoxane-3,4,5-triol;2-(2-hydroxypropoxy)propan-1-ol Chemical compound CC(O)COC(C)CO.CC(O)COC(C)CO.CC(O)COC(C)CO.CC(O)COC(C)CO.CO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O WQKLGQXWHKQTPO-UXRZSMILSA-N 0.000 description 1
- DSEKYWAQQVUQTP-XEWMWGOFSA-N (2r,4r,4as,6as,6as,6br,8ar,12ar,14as,14bs)-2-hydroxy-4,4a,6a,6b,8a,11,11,14a-octamethyl-2,4,5,6,6a,7,8,9,10,12,12a,13,14,14b-tetradecahydro-1h-picen-3-one Chemical compound C([C@H]1[C@]2(C)CC[C@@]34C)C(C)(C)CC[C@]1(C)CC[C@]2(C)[C@H]4CC[C@@]1(C)[C@H]3C[C@@H](O)C(=O)[C@@H]1C DSEKYWAQQVUQTP-XEWMWGOFSA-N 0.000 description 1
- BHMLFPOTZYRDKA-IRXDYDNUSA-N (2s)-2-[(s)-(2-iodophenoxy)-phenylmethyl]morpholine Chemical compound IC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 BHMLFPOTZYRDKA-IRXDYDNUSA-N 0.000 description 1
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- CHGIKSSZNBCNDW-UHFFFAOYSA-N (3beta,5alpha)-4,4-Dimethylcholesta-8,24-dien-3-ol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21 CHGIKSSZNBCNDW-UHFFFAOYSA-N 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- NKJOXAZJBOMXID-UHFFFAOYSA-N 1,1'-Oxybisoctane Chemical compound CCCCCCCCOCCCCCCCC NKJOXAZJBOMXID-UHFFFAOYSA-N 0.000 description 1
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- LQIAZOCLNBBZQK-UHFFFAOYSA-N 1-(1,2-Diphosphanylethyl)pyrrolidin-2-one Chemical compound PCC(P)N1CCCC1=O LQIAZOCLNBBZQK-UHFFFAOYSA-N 0.000 description 1
- BVMGAUOJVUEFSV-UHFFFAOYSA-N 1-(oxan-2-yl)indazol-6-amine Chemical compound C12=CC(N)=CC=C2C=NN1C1CCCCO1 BVMGAUOJVUEFSV-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- RZRNAYUHWVFMIP-KTKRTIGZSA-N 1-oleoylglycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-KTKRTIGZSA-N 0.000 description 1
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 1
- XYTLYKGXLMKYMV-UHFFFAOYSA-N 14alpha-methylzymosterol Natural products CC12CCC(O)CC1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C XYTLYKGXLMKYMV-UHFFFAOYSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- MKGZDUKUQPPHFM-CMDGGOBGSA-N 17-[(e)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one Chemical compound C1CC2=CC(=O)CCC2(C)C2C1C1CCC(C(C)/C=C/C(CC)C(C)C)C1(C)CC2 MKGZDUKUQPPHFM-CMDGGOBGSA-N 0.000 description 1
- 229940043268 2,2,4,4,6,8,8-heptamethylnonane Drugs 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- OBETXYAYXDNJHR-UHFFFAOYSA-N 2-Ethylhexanoic acid Chemical compound CCCCC(CC)C(O)=O OBETXYAYXDNJHR-UHFFFAOYSA-N 0.000 description 1
- FPVJYHHGNGJAPC-UHFFFAOYSA-N 2-[3-(decanoylamino)propyl-dimethylazaniumyl]acetate Chemical compound CCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O FPVJYHHGNGJAPC-UHFFFAOYSA-N 0.000 description 1
- SUZKAIPUWCLPCH-UHFFFAOYSA-N 2-[dimethyl-[3-(octanoylamino)propyl]azaniumyl]acetate Chemical group CCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O SUZKAIPUWCLPCH-UHFFFAOYSA-N 0.000 description 1
- GLCFQKXOQDQJFZ-UHFFFAOYSA-N 2-ethylhexyl 12-hydroxyoctadecanoate Chemical compound CCCCCCC(O)CCCCCCCCCCC(=O)OCC(CC)CCCC GLCFQKXOQDQJFZ-UHFFFAOYSA-N 0.000 description 1
- LCVHZNSIAYNAGX-UHFFFAOYSA-N 2-ethylhexyl 3,5,5-trimethylhexanoate Chemical compound CCCCC(CC)COC(=O)CC(C)CC(C)(C)C LCVHZNSIAYNAGX-UHFFFAOYSA-N 0.000 description 1
- FPKBRMRMNGYJLA-UHFFFAOYSA-M 2-hydroxyethyl-methyl-bis(2-octadecanoyloxyethyl)azanium;methyl sulfate Chemical compound COS([O-])(=O)=O.CCCCCCCCCCCCCCCCCC(=O)OCC[N+](C)(CCO)CCOC(=O)CCCCCCCCCCCCCCCCC FPKBRMRMNGYJLA-UHFFFAOYSA-M 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- MKGZDUKUQPPHFM-XJZKHKOHSA-N 24-ethyl-4,22-cholestadiene-3-one Natural products C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@@H](CC)C(C)C)[C@@]1(C)CC2 MKGZDUKUQPPHFM-XJZKHKOHSA-N 0.000 description 1
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 description 1
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 description 1
- XZEUYTKSAYNYPK-UHFFFAOYSA-N 3beta-29-Norcycloart-24-en-3-ol Natural products C1CC2(C)C(C(CCC=C(C)C)C)CCC2(C)C2CCC3C(C)C(O)CCC33C21C3 XZEUYTKSAYNYPK-UHFFFAOYSA-N 0.000 description 1
- FPTJELQXIUUCEY-UHFFFAOYSA-N 3beta-Hydroxy-lanostan Natural products C1CC2C(C)(C)C(O)CCC2(C)C2C1C1(C)CCC(C(C)CCCC(C)C)C1(C)CC2 FPTJELQXIUUCEY-UHFFFAOYSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- SJIDAAGFCNIAJP-UHFFFAOYSA-N 6-methylheptyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCCCCCC(C)C SJIDAAGFCNIAJP-UHFFFAOYSA-N 0.000 description 1
- LPEKGGXMPWTOCB-UHFFFAOYSA-N 8beta-(2,3-epoxy-2-methylbutyryloxy)-14-acetoxytithifolin Natural products COC(=O)C(C)O LPEKGGXMPWTOCB-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-M Acrylate Chemical compound [O-]C(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-M 0.000 description 1
- 235000009434 Actinidia chinensis Nutrition 0.000 description 1
- 244000298715 Actinidia chinensis Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 244000144927 Aloe barbadensis Species 0.000 description 1
- 235000002961 Aloe barbadensis Nutrition 0.000 description 1
- 239000004251 Ammonium lactate Substances 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 235000011437 Amygdalus communis Nutrition 0.000 description 1
- 235000011446 Amygdalus persica Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- 241000219310 Beta vulgaris subsp. vulgaris Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 235000007689 Borago officinalis Nutrition 0.000 description 1
- 240000004355 Borago officinalis Species 0.000 description 1
- 235000014698 Brassica juncea var multisecta Nutrition 0.000 description 1
- 235000006008 Brassica napus var napus Nutrition 0.000 description 1
- 240000000385 Brassica napus var. napus Species 0.000 description 1
- 235000006618 Brassica rapa subsp oleifera Nutrition 0.000 description 1
- 235000004977 Brassica sinapistrum Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 244000052707 Camellia sinensis Species 0.000 description 1
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000005940 Centaurea cyanus Nutrition 0.000 description 1
- 240000004385 Centaurea cyanus Species 0.000 description 1
- 235000007866 Chamaemelum nobile Nutrition 0.000 description 1
- 240000003538 Chamaemelum nobile Species 0.000 description 1
- 240000006162 Chenopodium quinoa Species 0.000 description 1
- 235000015493 Chenopodium quinoa Nutrition 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010008570 Chloasma Diseases 0.000 description 1
- 229920002567 Chondroitin Polymers 0.000 description 1
- 241000206575 Chondrus crispus Species 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 description 1
- 235000007716 Citrus aurantium Nutrition 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 235000001759 Citrus maxima Nutrition 0.000 description 1
- 244000276331 Citrus maxima Species 0.000 description 1
- 240000003791 Citrus myrtifolia Species 0.000 description 1
- 235000000228 Citrus myrtifolia Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 235000016646 Citrus taiwanica Nutrition 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000007460 Coffea arabica Nutrition 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 241001677238 Copernicia Species 0.000 description 1
- 235000010919 Copernicia prunifera Nutrition 0.000 description 1
- 244000180278 Copernicia prunifera Species 0.000 description 1
- 235000014493 Crataegus Nutrition 0.000 description 1
- 241001092040 Crataegus Species 0.000 description 1
- 244000241257 Cucumis melo Species 0.000 description 1
- 235000009842 Cucumis melo Nutrition 0.000 description 1
- RRTBTJPVUGMUNR-UHFFFAOYSA-N Cycloartanol Natural products C12CCC(C(C(O)CC3)(C)C)C3C2(CC)CCC2(C)C1(C)CCC2C(C)CCCC(C)C RRTBTJPVUGMUNR-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 1
- JDRSMPFHFNXQRB-CMTNHCDUSA-N Decyl beta-D-threo-hexopyranoside Chemical compound CCCCCCCCCCO[C@@H]1O[C@H](CO)C(O)[C@H](O)C1O JDRSMPFHFNXQRB-CMTNHCDUSA-N 0.000 description 1
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 description 1
- 206010012434 Dermatitis allergic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 206010012444 Dermatitis diaper Diseases 0.000 description 1
- 208000003105 Diaper Rash Diseases 0.000 description 1
- RDOFJDLLWVCMRU-UHFFFAOYSA-N Diisobutyl adipate Chemical compound CC(C)COC(=O)CCCCC(=O)OCC(C)C RDOFJDLLWVCMRU-UHFFFAOYSA-N 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- DNVPQKQSNYMLRS-NXVQYWJNSA-N Ergosterol Natural products CC(C)[C@@H](C)C=C[C@H](C)[C@H]1CC[C@H]2C3=CC=C4C[C@@H](O)CC[C@]4(C)[C@@H]3CC[C@]12C DNVPQKQSNYMLRS-NXVQYWJNSA-N 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 244000153517 Fragaria chiloensis Species 0.000 description 1
- 235000012652 Fragaria chiloensis Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 235000002873 Gentiana lutea Nutrition 0.000 description 1
- 240000003409 Gentiana lutea Species 0.000 description 1
- 235000008100 Ginkgo biloba Nutrition 0.000 description 1
- 244000194101 Ginkgo biloba Species 0.000 description 1
- BKLIAINBCQPSOV-UHFFFAOYSA-N Gluanol Natural products CC(C)CC=CC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(O)C(C)(C)C4CC3 BKLIAINBCQPSOV-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 description 1
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 1
- 244000303040 Glycyrrhiza glabra Species 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241001135694 Halomonadaceae Species 0.000 description 1
- 241000208681 Hamamelis virginiana Species 0.000 description 1
- 235000003222 Helianthus annuus Nutrition 0.000 description 1
- 244000020551 Helianthus annuus Species 0.000 description 1
- CMBYOWLFQAFZCP-UHFFFAOYSA-N Hexyl dodecanoate Chemical compound CCCCCCCCCCCC(=O)OCCCCCC CMBYOWLFQAFZCP-UHFFFAOYSA-N 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 235000017309 Hypericum perforatum Nutrition 0.000 description 1
- 244000141009 Hypericum perforatum Species 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 235000015164 Iris germanica var. florentina Nutrition 0.000 description 1
- HVXLSFNCWWWDPA-UHFFFAOYSA-N Isocycloartenol Natural products C1CC(O)C(C)(C)C2C31CC13CCC3(C)C(C(CCCC(C)=C)C)CCC3(C)C1CC2 HVXLSFNCWWWDPA-UHFFFAOYSA-N 0.000 description 1
- 241000592238 Juniperus communis Species 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- LOPKHWOTGJIQLC-UHFFFAOYSA-N Lanosterol Natural products CC(CCC=C(C)C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 LOPKHWOTGJIQLC-UHFFFAOYSA-N 0.000 description 1
- 229920002884 Laureth 4 Polymers 0.000 description 1
- 244000208060 Lawsonia inermis Species 0.000 description 1
- 235000004431 Linum usitatissimum Nutrition 0.000 description 1
- 240000006240 Linum usitatissimum Species 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000017011 Mandorlo dulce Nutrition 0.000 description 1
- 244000076313 Mandorlo dulce Species 0.000 description 1
- 240000007228 Mangifera indica Species 0.000 description 1
- 244000042664 Matricaria chamomilla Species 0.000 description 1
- 235000007232 Matricaria chamomilla Nutrition 0.000 description 1
- 241000219823 Medicago Species 0.000 description 1
- 241000378467 Melaleuca Species 0.000 description 1
- 241000366182 Melaleuca alternifolia Species 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001479543 Mentha x piperita Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000978725 Mimosa tenuiflora Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 125000001206 N(5)-methyl-L-glutamine group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C([H])([H])C([H])([H])C(N([H])C([H])([H])[H])=O 0.000 description 1
- SAVLIIGUQOSOEP-UHFFFAOYSA-N N-octanoylglycine Chemical compound CCCCCCCC(=O)NCC(O)=O SAVLIIGUQOSOEP-UHFFFAOYSA-N 0.000 description 1
- CAHGCLMLTWQZNJ-UHFFFAOYSA-N Nerifoliol Natural products CC12CCC(O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C)CCC21C CAHGCLMLTWQZNJ-UHFFFAOYSA-N 0.000 description 1
- 241001480177 Nymphaea alba Species 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- 235000004496 Oenothera biennis Nutrition 0.000 description 1
- 240000008916 Oenothera biennis Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 244000025272 Persea americana Species 0.000 description 1
- 235000011236 Persea americana var americana Nutrition 0.000 description 1
- 208000012641 Pigmentation disease Diseases 0.000 description 1
- HXQRIQXPGMPSRW-UHZRDUGNSA-N Pollinastanol Natural products O[C@@H]1C[C@H]2[C@@]3([C@]4([C@H]([C@@]5(C)[C@@](C)([C@H]([C@H](CCCC(C)C)C)CC5)CC4)CC2)C3)CC1 HXQRIQXPGMPSRW-UHZRDUGNSA-N 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- HDSBZMRLPLPFLQ-UHFFFAOYSA-N Propylene glycol alginate Chemical compound OC1C(O)C(OC)OC(C(O)=O)C1OC1C(O)C(O)C(C)C(C(=O)OCC(C)O)O1 HDSBZMRLPLPFLQ-UHFFFAOYSA-N 0.000 description 1
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical compound CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 108010009736 Protein Hydrolysates Proteins 0.000 description 1
- 235000009827 Prunus armeniaca Nutrition 0.000 description 1
- 244000018633 Prunus armeniaca Species 0.000 description 1
- 240000005809 Prunus persica Species 0.000 description 1
- 240000000528 Ricinus communis Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000000539 Rosa canina Nutrition 0.000 description 1
- 240000008530 Rosa canina Species 0.000 description 1
- 244000178231 Rosmarinus officinalis Species 0.000 description 1
- 241001092459 Rubus Species 0.000 description 1
- 235000003142 Sambucus nigra Nutrition 0.000 description 1
- 240000006028 Sambucus nigra Species 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 235000005318 Serenoa repens Nutrition 0.000 description 1
- 240000006661 Serenoa repens Species 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 1
- 239000004147 Sorbitan trioleate Substances 0.000 description 1
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 description 1
- 241001278026 Starmerella bombicola Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 235000021536 Sugar beet Nutrition 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000006468 Thea sinensis Nutrition 0.000 description 1
- 235000007303 Thymus vulgaris Nutrition 0.000 description 1
- 240000002657 Thymus vulgaris Species 0.000 description 1
- 235000015450 Tilia cordata Nutrition 0.000 description 1
- 240000007313 Tilia cordata Species 0.000 description 1
- PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 241000894477 Ulva compressa Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 241000209149 Zea Species 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- NCHJGQKLPRTMAO-XWVZOOPGSA-N [(2R)-2-[(2R,3R,4S)-3,4-dihydroxyoxolan-2-yl]-2-hydroxyethyl] 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NCHJGQKLPRTMAO-XWVZOOPGSA-N 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000001361 adipic acid Substances 0.000 description 1
- 235000011037 adipic acid Nutrition 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 150000008051 alkyl sulfates Chemical class 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000030961 allergic reaction Diseases 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
- 229940063655 aluminum stearate Drugs 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 229940059265 ammonium lactate Drugs 0.000 description 1
- 235000019286 ammonium lactate Nutrition 0.000 description 1
- BTBJBAZGXNKLQC-UHFFFAOYSA-N ammonium lauryl sulfate Chemical compound [NH4+].CCCCCCCCCCCCOS([O-])(=O)=O BTBJBAZGXNKLQC-UHFFFAOYSA-N 0.000 description 1
- 229940063953 ammonium lauryl sulfate Drugs 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000000149 argon plasma sintering Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- RZOBLYBZQXQGFY-HSHFZTNMSA-N azanium;(2r)-2-hydroxypropanoate Chemical compound [NH4+].C[C@@H](O)C([O-])=O RZOBLYBZQXQGFY-HSHFZTNMSA-N 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 229940073742 capramidopropyl betaine Drugs 0.000 description 1
- SHZIWNPUGXLXDT-UHFFFAOYSA-N caproic acid ethyl ester Natural products CCCCCC(=O)OCC SHZIWNPUGXLXDT-UHFFFAOYSA-N 0.000 description 1
- 229940051368 capryloyl glycine Drugs 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 229940106189 ceramide Drugs 0.000 description 1
- 150000001783 ceramides Chemical class 0.000 description 1
- 229940082500 cetostearyl alcohol Drugs 0.000 description 1
- 229960002788 cetrimonium chloride Drugs 0.000 description 1
- 229940085262 cetyl dimethicone Drugs 0.000 description 1
- 229940048851 cetyl ricinoleate Drugs 0.000 description 1
- YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 description 1
- 229960001927 cetylpyridinium chloride Drugs 0.000 description 1
- WOWHHFRSBJGXCM-UHFFFAOYSA-M cetyltrimethylammonium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+](C)(C)C WOWHHFRSBJGXCM-UHFFFAOYSA-M 0.000 description 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 description 1
- MRUAUOIMASANKQ-UHFFFAOYSA-N cocamidopropyl betaine Chemical compound CCCCCCCCCCCC(=O)NCCC[N+](C)(C)CC([O-])=O MRUAUOIMASANKQ-UHFFFAOYSA-N 0.000 description 1
- 229940073507 cocamidopropyl betaine Drugs 0.000 description 1
- 229940071160 cocoate Drugs 0.000 description 1
- 210000000795 conjunctiva Anatomy 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008406 cosmetic ingredient Substances 0.000 description 1
- 229920006037 cross link polymer Polymers 0.000 description 1
- ONQRKEUAIJMULO-YBXTVTTCSA-N cycloartenol Chemical compound CC(C)([C@@H](O)CC1)[C@H]2[C@@]31C[C@@]13CC[C@]3(C)[C@@H]([C@@H](CCC=C(C)C)C)CC[C@@]3(C)[C@@H]1CC2 ONQRKEUAIJMULO-YBXTVTTCSA-N 0.000 description 1
- YNBJLDSWFGUFRT-UHFFFAOYSA-N cycloartenol Natural products CC(CCC=C(C)C)C1CCC2(C)C1(C)CCC34CC35CCC(O)C(C)(C)C5CCC24C YNBJLDSWFGUFRT-UHFFFAOYSA-N 0.000 description 1
- FODTZLFLDFKIQH-UHFFFAOYSA-N cycloartenol trans-ferulate Natural products C1=C(O)C(OC)=CC(C=CC(=O)OC2C(C3CCC4C5(C)CCC(C5(C)CCC54CC53CC2)C(C)CCC=C(C)C)(C)C)=C1 FODTZLFLDFKIQH-UHFFFAOYSA-N 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229940073499 decyl glucoside Drugs 0.000 description 1
- SASYSVUEVMOWPL-NXVVXOECSA-N decyl oleate Chemical compound CCCCCCCCCCOC(=O)CCCCCCC\C=C/CCCCCCCC SASYSVUEVMOWPL-NXVVXOECSA-N 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 125000004188 dichlorophenyl group Chemical group 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- XXJWXESWEXIICW-UHFFFAOYSA-N diethylene glycol monoethyl ether Chemical compound CCOCCOCCO XXJWXESWEXIICW-UHFFFAOYSA-N 0.000 description 1
- 235000019961 diglycerides of fatty acid Nutrition 0.000 description 1
- QBSJHOGDIUQWTH-UHFFFAOYSA-N dihydrolanosterol Natural products CC(C)CCCC(C)C1CCC2(C)C3=C(CCC12C)C4(C)CCC(C)(O)C(C)(C)C4CC3 QBSJHOGDIUQWTH-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- YKZPPPNXRZHVGX-PXYKVGKMSA-L dipotassium;(2s)-2-aminobutanedioate;hydron;hydrate Chemical compound [H+].[H+].O.[K+].[K+].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O YKZPPPNXRZHVGX-PXYKVGKMSA-L 0.000 description 1
- 229940047642 disodium cocoamphodiacetate Drugs 0.000 description 1
- 229940079868 disodium laureth sulfosuccinate Drugs 0.000 description 1
- 229940079881 disodium lauroamphodiacetate Drugs 0.000 description 1
- ZPRZNBBBOYYGJI-UHFFFAOYSA-L disodium;2-[1-[2-(carboxylatomethoxy)ethyl]-2-undecyl-4,5-dihydroimidazol-1-ium-1-yl]acetate;hydroxide Chemical compound [OH-].[Na+].[Na+].CCCCCCCCCCCC1=NCC[N+]1(CCOCC([O-])=O)CC([O-])=O ZPRZNBBBOYYGJI-UHFFFAOYSA-L 0.000 description 1
- GLSRFBDXBWZNLH-UHFFFAOYSA-L disodium;2-chloroacetate;2-(4,5-dihydroimidazol-1-yl)ethanol;hydroxide Chemical compound [OH-].[Na+].[Na+].[O-]C(=O)CCl.OCCN1CCN=C1 GLSRFBDXBWZNLH-UHFFFAOYSA-L 0.000 description 1
- HQYLVDYBSIUTBB-UHFFFAOYSA-L disodium;3-[2-(2-carboxylatoethoxy)ethyl-[2-(dodecanoylamino)ethyl]amino]propanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCC(=O)NCCN(CCC([O-])=O)CCOCCC([O-])=O HQYLVDYBSIUTBB-UHFFFAOYSA-L 0.000 description 1
- YGAXLGGEEQLLKV-UHFFFAOYSA-L disodium;4-dodecoxy-4-oxo-2-sulfonatobutanoate Chemical compound [Na+].[Na+].CCCCCCCCCCCCOC(=O)CC(C([O-])=O)S([O-])(=O)=O YGAXLGGEEQLLKV-UHFFFAOYSA-L 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940030620 distearoylethyl hydroxyethylmonium methosulfate Drugs 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- QLVARBCGUNCRTA-LOYHVIPDSA-N ditetradecyl (2r,3r)-2,3-dihydroxybutanedioate Chemical compound CCCCCCCCCCCCCCOC(=O)[C@H](O)[C@@H](O)C(=O)OCCCCCCCCCCCCCC QLVARBCGUNCRTA-LOYHVIPDSA-N 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- XJFGDLJQUJQUEI-UHFFFAOYSA-N dodecyl decanoate dodecyl octanoate Chemical compound CCCCCCCCCCCCOC(=O)CCCCCCC.CCCCCCCCCCCCOC(=O)CCCCCCCCC XJFGDLJQUJQUEI-UHFFFAOYSA-N 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- OYFJQPXVCSSHAI-QFPUQLAESA-N enalapril maleate Chemical compound OC(=O)\C=C/C(O)=O.C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 OYFJQPXVCSSHAI-QFPUQLAESA-N 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- DNVPQKQSNYMLRS-SOWFXMKYSA-N ergosterol Chemical compound C1[C@@H](O)CC[C@]2(C)[C@H](CC[C@]3([C@H]([C@H](C)/C=C/[C@@H](C)C(C)C)CC[C@H]33)C)C3=CC=C21 DNVPQKQSNYMLRS-SOWFXMKYSA-N 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N ethylene glycol Natural products OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229940100549 ethylhexyl isononanoate Drugs 0.000 description 1
- 235000008995 european elder Nutrition 0.000 description 1
- 229940045761 evening primrose extract Drugs 0.000 description 1
- 235000008524 evening primrose extract Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 229940043259 farnesol Drugs 0.000 description 1
- 229930002886 farnesol Natural products 0.000 description 1
- 235000001785 ferulic acid Nutrition 0.000 description 1
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 1
- 229940114124 ferulic acid Drugs 0.000 description 1
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 235000004426 flaxseed Nutrition 0.000 description 1
- 238000005187 foaming Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 229940074046 glyceryl laurate Drugs 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 239000003676 hair preparation Substances 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- XAMHKORMKJIEFW-AYTKPMRMSA-N hexadecyl (z,12r)-12-hydroxyoctadec-9-enoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC\C=C/C[C@H](O)CCCCCC XAMHKORMKJIEFW-AYTKPMRMSA-N 0.000 description 1
- FBQVFXLUGAFMIO-UHFFFAOYSA-N hexadecyl 16-methylheptadecanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCCCC(C)C FBQVFXLUGAFMIO-UHFFFAOYSA-N 0.000 description 1
- XJNUECKWDBNFJV-UHFFFAOYSA-N hexadecyl 2-ethylhexanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)C(CC)CCCC XJNUECKWDBNFJV-UHFFFAOYSA-N 0.000 description 1
- PMMXXYHTOMKOAZ-UHFFFAOYSA-N hexadecyl 7-methyloctanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCC(C)C PMMXXYHTOMKOAZ-UHFFFAOYSA-N 0.000 description 1
- DWMMZQMXUWUJME-UHFFFAOYSA-N hexadecyl octanoate Chemical compound CCCCCCCCCCCCCCCCOC(=O)CCCCCCC DWMMZQMXUWUJME-UHFFFAOYSA-N 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 229940100463 hexyl laurate Drugs 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 229940057871 hydrogenated palm glycerides Drugs 0.000 description 1
- 229920006007 hydrogenated polyisobutylene Polymers 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 244000023249 iris florentino Species 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- KUVMKLCGXIYSNH-UHFFFAOYSA-N isopentadecane Natural products CCCCCCCCCCCCC(C)C KUVMKLCGXIYSNH-UHFFFAOYSA-N 0.000 description 1
- 229940093629 isopropyl isostearate Drugs 0.000 description 1
- 229940074928 isopropyl myristate Drugs 0.000 description 1
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229940058690 lanosterol Drugs 0.000 description 1
- CAHGCLMLTWQZNJ-RGEKOYMOSA-N lanosterol Chemical compound C([C@]12C)C[C@@H](O)C(C)(C)[C@H]1CCC1=C2CC[C@]2(C)[C@H]([C@H](CCC=C(C)C)C)CC[C@@]21C CAHGCLMLTWQZNJ-RGEKOYMOSA-N 0.000 description 1
- 238000002356 laser light scattering Methods 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940100556 laureth-23 Drugs 0.000 description 1
- 229940061515 laureth-4 Drugs 0.000 description 1
- PYIDGJJWBIBVIA-UYTYNIKBSA-N lauryl glucoside Chemical compound CCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O PYIDGJJWBIBVIA-UYTYNIKBSA-N 0.000 description 1
- 229940048848 lauryl glucoside Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229960001983 magnesium aspartate Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 229940037627 magnesium lauryl sulfate Drugs 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- RXMQCXCANMAVIO-CEOVSRFSSA-L magnesium;(2s)-2-amino-4-hydroxy-4-oxobutanoate Chemical compound [H+].[H+].[Mg+2].[O-]C(=O)[C@@H](N)CC([O-])=O.[O-]C(=O)[C@@H](N)CC([O-])=O RXMQCXCANMAVIO-CEOVSRFSSA-L 0.000 description 1
- HBNDBUATLJAUQM-UHFFFAOYSA-L magnesium;dodecyl sulfate Chemical compound [Mg+2].CCCCCCCCCCCCOS([O-])(=O)=O.CCCCCCCCCCCCOS([O-])(=O)=O HBNDBUATLJAUQM-UHFFFAOYSA-L 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000001771 mentha piperita Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 229940057867 methyl lactate Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 235000019426 modified starch Nutrition 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 229940078812 myristyl myristate Drugs 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- BOUCRWJEKAGKKG-UHFFFAOYSA-N n-[3-(diethylaminomethyl)-4-hydroxyphenyl]acetamide Chemical compound CCN(CC)CC1=CC(NC(C)=O)=CC=C1O BOUCRWJEKAGKKG-UHFFFAOYSA-N 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- ZVVSSOQAYNYNPP-UHFFFAOYSA-N olaflur Chemical compound F.F.CCCCCCCCCCCCCCCCCCN(CCO)CCCN(CCO)CCO ZVVSSOQAYNYNPP-UHFFFAOYSA-N 0.000 description 1
- 229960001245 olaflur Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 235000021313 oleic acid Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 229940055726 pantothenic acid Drugs 0.000 description 1
- 235000019161 pantothenic acid Nutrition 0.000 description 1
- 239000011713 pantothenic acid Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229940055076 parasympathomimetics choline ester Drugs 0.000 description 1
- 238000003921 particle size analysis Methods 0.000 description 1
- 229940100460 peg-100 stearate Drugs 0.000 description 1
- 229940086539 peg-7 glyceryl cocoate Drugs 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000019612 pigmentation Effects 0.000 description 1
- SATCULPHIDQDRE-UHFFFAOYSA-N piperonal Chemical compound O=CC1=CC=C2OCOC2=C1 SATCULPHIDQDRE-UHFFFAOYSA-N 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 229920000151 polyglycol Polymers 0.000 description 1
- 239000010695 polyglycol Substances 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 150000008442 polyphenolic compounds Chemical class 0.000 description 1
- 235000013824 polyphenols Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 229940068988 potassium aspartate Drugs 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 229940116393 ppg-20 methyl glucose ether Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- NEOZOXKVMDBOSG-UHFFFAOYSA-N propan-2-yl 16-methylheptadecanoate Chemical compound CC(C)CCCCCCCCCCCCCCC(=O)OC(C)C NEOZOXKVMDBOSG-UHFFFAOYSA-N 0.000 description 1
- 235000010409 propane-1,2-diol alginate Nutrition 0.000 description 1
- 239000000770 propane-1,2-diol alginate Substances 0.000 description 1
- 239000000473 propyl gallate Substances 0.000 description 1
- 235000010388 propyl gallate Nutrition 0.000 description 1
- 229940075579 propyl gallate Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 239000003531 protein hydrolysate Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 150000003248 quinolines Chemical class 0.000 description 1
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 229960003471 retinol Drugs 0.000 description 1
- 235000020944 retinol Nutrition 0.000 description 1
- 239000011607 retinol Substances 0.000 description 1
- 229940066675 ricinoleate Drugs 0.000 description 1
- 235000015639 rosmarinus officinalis Nutrition 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 235000017709 saponins Nutrition 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 235000003441 saturated fatty acids Nutrition 0.000 description 1
- 150000004671 saturated fatty acids Chemical class 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
- 235000015500 sitosterol Nutrition 0.000 description 1
- 229950005143 sitosterol Drugs 0.000 description 1
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 description 1
- 231100000046 skin rash Toxicity 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 229940096501 sodium cocoamphoacetate Drugs 0.000 description 1
- 229940057950 sodium laureth sulfate Drugs 0.000 description 1
- 229940075560 sodium lauryl sulfoacetate Drugs 0.000 description 1
- RYYKJJJTJZKILX-UHFFFAOYSA-M sodium octadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCCCC([O-])=O RYYKJJJTJZKILX-UHFFFAOYSA-M 0.000 description 1
- 229940045870 sodium palmitate Drugs 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 1
- 235000019345 sodium thiosulphate Nutrition 0.000 description 1
- GOJYXPWOUJYXJC-UHFFFAOYSA-M sodium;2-[1-(2-hydroxyethyl)-2-undecyl-4,5-dihydroimidazol-1-ium-1-yl]acetate;hydroxide Chemical compound [OH-].[Na+].CCCCCCCCCCCC1=NCC[N+]1(CCO)CC([O-])=O GOJYXPWOUJYXJC-UHFFFAOYSA-M 0.000 description 1
- SXHLENDCVBIJFO-UHFFFAOYSA-M sodium;2-[2-(2-dodecoxyethoxy)ethoxy]ethyl sulfate Chemical compound [Na+].CCCCCCCCCCCCOCCOCCOCCOS([O-])(=O)=O SXHLENDCVBIJFO-UHFFFAOYSA-M 0.000 description 1
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 description 1
- CRPCXAMJWCDHFM-UHFFFAOYSA-M sodium;5-oxopyrrolidine-2-carboxylate Chemical compound [Na+].[O-]C(=O)C1CCC(=O)N1 CRPCXAMJWCDHFM-UHFFFAOYSA-M 0.000 description 1
- GGXKEBACDBNFAF-UHFFFAOYSA-M sodium;hexadecanoate Chemical compound [Na+].CCCCCCCCCCCCCCCC([O-])=O GGXKEBACDBNFAF-UHFFFAOYSA-M 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 235000011069 sorbitan monooleate Nutrition 0.000 description 1
- 239000001593 sorbitan monooleate Substances 0.000 description 1
- 229940035049 sorbitan monooleate Drugs 0.000 description 1
- 235000011076 sorbitan monostearate Nutrition 0.000 description 1
- 239000001587 sorbitan monostearate Substances 0.000 description 1
- 229940035048 sorbitan monostearate Drugs 0.000 description 1
- 229960005078 sorbitan sesquioleate Drugs 0.000 description 1
- 235000019337 sorbitan trioleate Nutrition 0.000 description 1
- 229960000391 sorbitan trioleate Drugs 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229940073743 steareth-20 methacrylate Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940012831 stearyl alcohol Drugs 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- IZEUIYYDWBKERE-UHFFFAOYSA-N stigmasteryl acetate Natural products C1C=C2CC(OC(C)=O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 IZEUIYYDWBKERE-UHFFFAOYSA-N 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- DZKXJUASMGQEMA-UHFFFAOYSA-N tetradecyl tetradecanoate Chemical compound CCCCCCCCCCCCCCOC(=O)CCCCCCCCCCCCC DZKXJUASMGQEMA-UHFFFAOYSA-N 0.000 description 1
- 125000000383 tetramethylene group Chemical group [H]C([H])([*:1])C([H])([H])C([H])([H])C([H])([H])[*:2] 0.000 description 1
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 description 1
- 239000001585 thymus vulgaris Substances 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- CRDAMVZIKSXKFV-UHFFFAOYSA-N trans-Farnesol Natural products CC(C)=CCCC(C)=CCCC(C)=CCO CRDAMVZIKSXKFV-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- GVPDNFYOFKBFEN-UHFFFAOYSA-N trimethyl(octadecoxy)silane Chemical compound CCCCCCCCCCCCCCCCCCO[Si](C)(C)C GVPDNFYOFKBFEN-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 235000021122 unsaturated fatty acids Nutrition 0.000 description 1
- 150000004670 unsaturated fatty acids Chemical class 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 239000003021 water soluble solvent Substances 0.000 description 1
- 229920003169 water-soluble polymer Polymers 0.000 description 1
- 230000029663 wound healing Effects 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 230000037373 wrinkle formation Effects 0.000 description 1
- 230000037303 wrinkles Effects 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/14—Liposomes; Vesicles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
- A61K8/42—Amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
- A61K8/4953—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom containing pyrimidine ring derivatives, e.g. minoxidil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/99—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from microorganisms other than algae or fungi, e.g. protozoa or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q1/00—Make-up preparations; Body powders; Preparations for removing make-up
- A61Q1/02—Preparations containing skin colorants, e.g. pigments
- A61Q1/10—Preparations containing skin colorants, e.g. pigments for eyes, e.g. eyeliner, mascara
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
- A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/10—Washing or bathing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/02—Preparations for cleaning the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/06—Preparations for styling the hair, e.g. by temporary shaping or colouring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
- A61Q5/12—Preparations containing hair conditioners
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/412—Microsized, i.e. having sizes between 0.1 and 100 microns
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/41—Particular ingredients further characterized by their size
- A61K2800/413—Nanosized, i.e. having sizes below 100 nm
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/56—Compounds, absorbed onto or entrapped into a solid carrier, e.g. encapsulated perfumes, inclusion compounds, sustained release forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/60—Particulates further characterized by their structure or composition
- A61K2800/65—Characterized by the composition of the particulate/core
- A61K2800/652—The particulate/core comprising organic material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 판테놀 및 니오좀을 유효성분으로 포함하는 피부 개선용 화장료 조성물에 관한 것으로, 상세하게는 판테놀, 엑토인 및 알란토인의 유효성분을 니오좀 내에 담지함으로써 상기 유효성분들의 안정성을 높이고 용해성 및 피부 침투율을 증가시킴과 동시에 피부진정, 자극완화, 지속적인 보습 등의 효과를 높일 수 있는 판테놀 및 니오좀을 유효성분으로 포함하는 피부 개선용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for skin improvement comprising panthenol and niosome as active ingredients, and in detail, by containing the active ingredients of panthenol, ectoin and allantoin in niosome to increase the stability of the active ingredients, solubility and skin The present invention relates to a cosmetic composition for skin improvement containing panthenol and niosome as active ingredients capable of increasing the penetration rate and at the same time increasing effects such as skin soothing, irritation relief, and continuous moisturizing.
일반적으로 피부에 자극을 완화하거나 지속적인 보습을 가져다주는 유효성분들은 분자량이 매우 크기 때문에 피부에 흡수되기가 어렵다. 따라서, 이러한 유효성분이 피부에 침투할 수 있도록 입자의 크기를 조절하는 것이 매우 중요하다.In general, active ingredients that relieve skin irritation or provide continuous moisturizing are difficult to be absorbed into the skin because they have a very large molecular weight. Therefore, it is very important to control the size of the particles so that these active ingredients can penetrate the skin.
통상 만들어지는 나노에멀젼은 나노리포좀이며, 리포좀은 지질이중막으로 형성되는 폐쇄된 소포이고, 그 소포공간내에 수상의 미용성분을 포함한다. 리포좀으로는 SUV(small unilamellar Vesicle), LUV(Large unilamellar Vesicle), GUV(giant unilamellar Vesicle)와 같은 이중막 구조가 알려져 있고, 이러한 이중막이 5개 이상 이루어지는 것을 멀티 라멜라 소포체(MLV, Multilamellar Vesicle)라고 한다.A nanoemulsion usually made is a nanoliposome, and a liposome is a closed vesicle formed of a lipid bilayer, and contains cosmetic ingredients in the aqueous phase within the vesicle space. As for liposomes, double membrane structures such as SUV (small unilamellar vesicle), LUV (large unilamellar vesicle), and GUV (giant unilamellar vesicle) are known, and multilamellar vesicles (MLV) are composed of five or more such double membranes. do.
이러한 일반적인 나노에멀젼이 폐쇄된 소포 안에 액체의 유상성분을 포접할 수 있는데 이러한 나노에멀젼은 외부의 수상과 삼투 작용에 의해 포접된 유상성분이 파괴될 수 있다, 이를 방지하기 위하여 액체의 유상성분을 고체의 리피드로 만든 것이 SLN(soild Lipid Nanoparticle)인데 이러한 SLN은 외부와 삼투작용이 적어 유효성분이 잘 보전된다. 그러나, 유상성분을 고체 리피드로 하기 때문에 시간이 지나감에 따라 나노에멀젼이 굳는 현상이 생긴다, 이러한 단점을 보완하고자 오일을 5 내지 10 중량% 정도 첨가하여 나노에멀젼이 굳는 현상을 막는다(NLC).These general nanoemulsions can entrap liquid oil components in closed vesicles, and these nanoemulsions can destroy the entrapped oil components by osmotic action with the external water phase. To prevent this, the liquid oil components are solidified. SLN (soiled Lipid Nanoparticle) is made of lipids, and these SLNs have little external and osmotic action, so active ingredients are well preserved. However, since the oily component is a solid lipid, the nanoemulsion hardens over time. In order to compensate for this drawback, oil is added in an amount of 5 to 10% by weight to prevent the nanoemulsion from hardening (NLC).
또한, 기존의 리포좀은 리포좀 벽이 탄력적이지 못하기 때문에 유효성분을 피부 깊숙이 침투시키지 못하므로 이러한 리포좀 벽을 탄력적으로 만들어서 피부침투를 원활하게 만든 것이 트랜스퍼좀(탄성리포좀/탄력리포좀/플렉시블리포좀)이라 불린다.In addition, conventional liposomes cannot penetrate the active ingredients deep into the skin because the walls of the liposomes are not elastic. Therefore, transfersomes (elastic liposomes/elastic liposomes/flexible liposomes) make the walls of these liposomes elastic to facilitate skin penetration. is called
니오좀(Niosome)은 비이온성 계면활성제로 구성된 이중막 수송체로 생분해성이며 극성 및 비극성 물질을 봉입할 수 있고 리포좀에 비하여 안정하여 리포좀의 대규모 생산 및 안정성과 관련된 문제를 극복하기 위한 대안으로 개발되고 있다.Niosome is a double-membrane transporter composed of nonionic surfactants that is biodegradable, can encapsulate polar and non-polar substances, and is more stable than liposomes. there is.
니오좀과 리포좀은 구조적으로 유사하지만 니오좀은 전하가 없는 단일 사슬 계면활성제 및 콜레스테롤로부터 제조되는 반면 리포좀은 이중사슬 인지질으로부터 제조되기 때문에 리포좀과 니오좀 사이에 특성 차이가 존재한다. 이들 소포체의 안정화는 막(Membrances)을 유지시켜 주는 콜레스테롤 성분에 의해 좌우된다. 비이온 계면활성제로 구성된 니오좀은 비이온 계면활성제 자체만으로는 지질과 같은 역할을 기대할 수 없고 천연 지질성분과 유사하도록 만들어야 하는데 주로 이용되는 것이 글리세린(Glycerine) 골격에 인산염(Phosphate) 유도체를 접목시켜 양친매성 성질을 갖도록 만들어 사용한다. 니오좀은 극성 및 비극성 물질을 봉입할 수 있고, 삼투압적으로 활성이 있으며, 제조 시 사용되는 계면활성제가 보관 및 취급에 특별한 조건이 필요하지 않다는 장점이 있다.Although niosomes and liposomes are structurally similar, differences in properties exist between liposomes and niosomes because niosomes are prepared from uncharged single-chain surfactants and cholesterol, whereas liposomes are prepared from double-chain phospholipids. Stabilization of these endoplasmic reticulum is governed by cholesterol components that maintain membranes (Membrances). Niosomes composed of nonionic surfactants cannot be expected to play the same role as lipids with only the nonionic surfactants themselves, and must be made similar to natural lipid components. It is used to make it have masculine properties. Niosomes are advantageous in that they can encapsulate polar and non-polar substances, are osmotically active, and do not require special conditions for storage and handling of surfactants used in their preparation.
한편, 판테놀(Panthenol)은 비타민 B5의 전구체로서, 체내에서 분해되어 판토텐산으로 전환된다. 판테놀은 피부의 보습 유지기능을 향상시키는 효과를 가지는 것이 이미 알려져 있어, 발진크림과 연고 등에 널리 사용된다. 특히, 판테놀이 5% 함량으로 포함될 경우 피부 보호막 강화, 피부 재생, 수분 공급에 현저한 효능이 있는 것으로 알려져 있다.On the other hand, panthenol (Panthenol) is a precursor of vitamin B5, which is decomposed in the body and converted into pantothenic acid. Panthenol is already known to have an effect of improving the skin's ability to retain moisture, and is widely used in rash creams and ointments. In particular, when panthenol is included in an amount of 5%, it is known to have remarkable effects on strengthening the skin barrier, regenerating the skin, and supplying moisture.
판테놀의 피부 보습 및 피부 보호막 복원 능력이 표피 재생을 촉진함에 따라 아토피 피부염과 기저귀 발진에 국부적으로 도포된다. 또한, 섬유아세포의 증식과 상피화를 촉진시켜 상처 치유를 촉진할 수 있다. 연구 결과, 5% 판테놀 에멀전은 홍반테마 감소와 탄성 및 고체조직 재생 증가(Proksch, 등., 2017)를 유도하고, 5% D-판테놀을 매일 적용하면 유두 균열 완화 가능성이 있는 것으로 나타났다(Kus, 등., 2002). 나아가 D-판테놀은 피부 이식과 화상으로 인한 흉터를 매일 관리하는 데 좋은 영향을 미친다(Buttemeyer, 등., 1995).Panthenol is topically applied to atopic dermatitis and diaper rash as its ability to moisturize the skin and restore the skin barrier promotes epidermal regeneration. In addition, it can promote wound healing by promoting proliferation and epithelialization of fibroblasts. As a result of the study, it was found that 5% panthenol emulsion induces reduction of erythema theme and increase in elasticity and solid tissue regeneration (Proksch, et al., 2017), and daily application of 5% D-panthenol has the potential to alleviate nipple cracks (Kus, et al., 2017). et al., 2002). Furthermore, D-panthenol has a good effect on daily management of scars caused by skin grafts and burns (Buttemeyer, et al., 1995).
그러나 판테놀의 함량을 증가시킨 로션 등의 형태를 갖는 판테놀 및 니오좀을 유효성분으로 포함하는 피부 개선용 화장료 조성물들은 상기 판테놀이나 니오좀의 함량을 고농도로 유지하는 경우 흡수성 제품에 적용하기에 제조와 도포 과정에서 안정성이 떨어지는 문제를 가지고 있다. 특히 판테놀은 친수성을 가지기 때문에 고농도로 포함될 경우 기존 왁스 베이스 제형에서 불안정성을 보이며, 제조과정에서 침전되는 경향을 보인다. 여기에 사람에 따라 덱스판테놀이 알러지의 항원으로 작용하여 사람에 따라 알러지 접촉성 피부염을 야기시키는 문제점도 가지고 있다.However, cosmetic compositions for skin improvement containing panthenol and niosome in the form of a lotion with increased panthenol content as active ingredients are manufactured and applied to absorbent products when the content of panthenol or niosome is maintained at a high concentration. It has a problem of poor stability in the application process. In particular, since panthenol has hydrophilicity, when it is included in a high concentration, it shows instability in conventional wax-based formulations and tends to precipitate during the manufacturing process. Here, depending on the person, dexpanthenol acts as an allergen, causing allergic contact dermatitis in some people.
본 발명은 상기와 같은 문제점을 해결하기 위해 안출한 것으로, 상세하게는 판테놀, 엑토인 및 알란토인의 유효성분을 니오좀 내에 담지함으로써 상기 유효성분들의 안정성을 높이고 용해성 및 피부 침투율을 증가시킴과 동시에 판테놀의 부작용인 알러지 항원 작용을 억제하면서도 피부진정, 자극완화, 지속적인 보습 등의 효과를 높일 수 있는 판테놀 및 니오좀을 유효성분으로 포함하는 피부 개선용 화장료 조성물에 관한 것이다.The present invention has been made to solve the above problems, and in detail, by carrying the active ingredients of panthenol, ectoin and allantoin in niosome, the stability of the active ingredients is increased, solubility and skin penetration rate are increased, and at the same time, panthenol It relates to a cosmetic composition for skin improvement containing panthenol and niosome as active ingredients capable of enhancing effects such as skin soothing, irritation relief, and continuous moisturizing while suppressing the side effect of allergens.
본 발명은 판테놀 및 니오좀을 유효성분으로 포함하는 피부 개선용 화장료 조성물에 관한 것이다.The present invention relates to a cosmetic composition for skin improvement comprising panthenol and niosome as active ingredients.
본 발명의 일 양태는 내부에 판테놀, 엑토인 및 알란토인이 담지된 니오좀을 포함하는 판테놀 및 니오좀을 유효성분으로 포함하는 피부 개선용 화장료 조성물에 관한 것이다.One aspect of the present invention relates to a cosmetic composition for skin improvement comprising panthenol and niosome containing panthenol, ectoin and allantoin supported therein as active ingredients.
본 발명에서 상기 판테놀, 엑토인 및 알란토인은 각각 니오좀 총 중량에 대하여 0.001 내지 10 중량%의 양으로 함유될 수 있으며, 상기 니오좀은 비이온계 계면활성제, 콜레스테롤, 보조유화제 및 안정화제를 포함하여 형성될 수 있다.In the present invention, the panthenol, ectoin, and allantoin may each be contained in an amount of 0.001 to 10% by weight based on the total weight of niosome, and the niosome includes a nonionic surfactant, cholesterol, a co-emulsifier, and a stabilizer can be formed by
또한 상기 니오좀은 평균입경이 10 내지 200㎚이며, 상기 조성물은 전체 100 중량% 중 니오좀을 0.1 내지 10 중량% 포함할 수 있다.In addition, the niosome has an average particle diameter of 10 to 200 nm, and the composition may include 0.1 to 10 wt% of niosome based on 100 wt% of the total.
여기에 상기 조성물은 스킨, 에멀젼, 크림, 선크림, 파운데이션, 에센스, 젤, 팩, 마스크팩, 폼클렌저, 바디클렌저, 유연화장수, 아이라이너, 샴푸, 린스, 비누, 정발제, 양모제, 헤어크림, 헤어 스타일링젤, 윤활제, 치약, 에어로졸 및 경피패치로 이루어진 군에서 선택된 어느 하나의 제형을 가질 수 있다.Here, the composition is skin, emulsion, cream, sunscreen, foundation, essence, gel, pack, mask pack, foam cleanser, body cleanser, softening lotion, eyeliner, shampoo, conditioner, soap, hairdressing agent, hair conditioner, hair cream, It may have any one formulation selected from the group consisting of hair styling gel, lubricant, toothpaste, aerosol, and transdermal patch.
본 발명에 따른 피부 개선용 화장료 조성물은 판테놀, 엑토인 및 알란토인의 유효성분을 니오좀 내에 담지함으로써 상기 유효성분들의 안정성을 높이고 용해성 및 피부 침투율을 증가시킴과 동시에 판테놀의 부작용인 알러지 항원 작용을 억제하면서도 피부진정, 자극완화, 지속적인 보습 등의 효과를 높일 수 있다.The cosmetic composition for skin improvement according to the present invention contains active ingredients of panthenol, ectoin, and allantoin in niosome, thereby increasing the stability of the active ingredients, increasing solubility and skin penetration rate, and at the same time suppressing allergen action, which is a side effect of panthenol It can increase the effect of skin soothing, irritation relief, and continuous moisturizing.
이하, 구체적인 실시예를 통해 본 발명에 따른 판테놀 및 니오좀을 유효성분으로 포함하는 피부 개선용 화장료 조성물을 더욱 상세히 설명한다. 다음에 소개되는 구체예들은 당업자에게 본 발명의 사상이 충분히 전달될 수 있도록 하기 위해 예로서 제공되는 것이다.Hereinafter, the cosmetic composition for skin improvement containing panthenol and niosome as active ingredients according to the present invention will be described in more detail through specific examples. The specific examples introduced below are provided as examples to sufficiently convey the spirit of the present invention to those skilled in the art.
따라서 본 발명은 이하 제시되는 구체예들에 한정되지 않고 다른 형태로 구체화될 수도 있으며, 이하 제시되는 구체예들은 본 발명의 사상을 명확히 하기 위해 기재된 것일 뿐, 본 발명이 이에 제한되는 것은 아니다.Therefore, the present invention may be embodied in other forms without being limited to the specific examples presented below, and the specific examples presented below are only described to clarify the spirit of the present invention, but the present invention is not limited thereto.
이때, 사용되는 기술 용어 및 과학 용어에 있어서 다른 정의가 없다면, 이 발명이 속하는 기술 분야에서 통상의 지식을 가진 자가 통상적으로 이해하고 있는 의미를 가지며, 하기의 설명에서 본 발명의 요지를 불필요하게 흐릴 수 있는 공지 기능 및 구성에 대한 설명은 생략한다.At this time, if there is no other definition in the technical terms and scientific terms used, they have meanings commonly understood by those of ordinary skill in the art to which this invention belongs, and will unnecessarily obscure the gist of the present invention in the following description. Descriptions of possible known functions and configurations are omitted.
또한 명세서 및 첨부된 특허청구범위에서 사용되는 단수 형태는 문맥에서 특별한 지시가 없는 한 복수 형태도 포함하는 것으로 의도할 수 있다.Also, the singular forms used in the specification and appended claims may be intended to include the plural forms as well, unless the context dictates otherwise.
또한, 본 발명의 구성 요소를 설명하는 데 있어서, 제 1, 제 2, A, B, (a), (b) 등의 용어를 사용할 수 있다. 이러한 용어는 그 구성 요소를 다른 구성 요소와 구별하기 위한 것일 뿐, 그 용어에 의해 해당 구성 요소의 본질이나 차례 또는 순서 등이 한정되지 않는다. 어떤 구성 요소가 다른 구성요소에 "연결", "결합" 또는 "접속"된다고 기재된 경우, 그 구성 요소는 그 다른 구성요소에 직접적으로 연결되거나 또는 접속될 수 있지만, 각 구성 요소 사이에 또 다른 구성 요소가 "연결", "결합" 또는 "접속"될 수도 있다고 이해되어야 할 것이다.Also, terms such as first, second, A, B, (a), and (b) may be used in describing the components of the present invention. These terms are only used to distinguish the component from other components, and the nature, order, or order of the corresponding component is not limited by the term. When an element is described as being “connected,” “coupled to,” or “connected” to another element, that element is directly connected or connectable to the other element, but there is another element between the elements. It will be understood that elements may be “connected”, “coupled” or “connected”.
본 발명에서 용어 ‘피부 외용제’란 피부에 적용하는 조성물 전반을 포괄하는 개념으로, 예를 들어, 기초 화장료, 메이크업 화장료, 모발용 화장료 등 각종 화장료; 연고제, 크림제, 로션제 등 의약품 및 의약부외품을 포함한 피부 외용으로 적용되는 약학 조성물 등을 포함하는 개념이다.In the present invention, the term 'external skin preparation' is a concept encompassing the overall composition applied to the skin, and includes, for example, various cosmetics such as basic cosmetics, makeup cosmetics, and hair cosmetics; It is a concept that includes pharmaceutical compositions applied externally to the skin, including pharmaceuticals and quasi-drugs such as ointments, creams, and lotions.
본 발명에서 용어, ‘니오좀(noisome)’은 비이온성 계면활성제 기반 소포(non-ionic surfactant-based vesicle)로서, 내부에는 친수성 공간이 형성되어 있고, 외부에는 소수성의 성질을 갖는 닫힌 이중 지질 막을 가지고 있는 미세 분자체를 의미한다.In the present invention, the term 'noisome' is a non-ionic surfactant-based vesicle, which has a hydrophilic space inside and a closed double lipid membrane with hydrophobic properties on the outside. It means a fine molecular sieve that has
용어, ‘비이온성 계면활성제(non-ionic surfactant)’는 이온으로 분리되지 않는 계면활성제로서, 비이온 활성제 또는 비이온 표면활성제라고도 한다. 비이온 계면활성제는 그 성질이 이온 계면활성제와는 달리 다른 계면활성제나 전해질과도 마음대로 혼합할 수 있다. 피부에 대한 반응이 무해하며, 샴푸기제의 증점, 저온에서의 안정성 향상, 세척 작용이 우수하면서도 거품이 덜 생기는 등의 특성이 있어 분산제, 에멀젼제, 세정제, 염색조제 등의 다양한 용도로 사용할 수 있다.The term ‘non-ionic surfactant’ is a surfactant that is not separated into ions, and is also referred to as non-ionic surfactant or non-ionic surfactant. Unlike ionic surfactants, nonionic surfactants can be freely mixed with other surfactants or electrolytes. It is harmless to the skin, thickens the shampoo base, improves stability at low temperatures, and has excellent washing action but less foaming, so it can be used for various purposes such as dispersing agent, emulsion agent, detergent, and dyeing aid. .
본 발명에서 상기 판테놀 및 니오좀을 유효성분으로 포함하는 피부 개선용 화장료 조성물은 내부에 판테놀, 엑토인 및 알란토인이 담지된 니오좀을 포함할 수 있다.In the present invention, the cosmetic composition for skin improvement containing panthenol and niosome as active ingredients may include panthenol, ectoin, and allantoin niosome loaded therein.
상기 판테놀(Panthenol)은 체내에서 비타민 B5로 변환되는 프로비타민 B5라고도 하는 수용성 프로비타민을 의미하며 염증 매개체인 프로스타그란딘(prostaglandin), 류코트리엔(lukotriene)을 대사하는 싸이크로옥시게나아제의 활성을 억제하여 가려움을 방지하거나 피부 점막에 보습성을 부여한다. 또한 세포 성장을 촉진하고 피부의 보습을 유지하는 기능을 하며, 피부 점막에 윤기를 제공하고, 주름, 탄력, 기미 등 피부 노화를 예방하는 효과가 있다.The panthenol refers to a water-soluble provitamin, also called provitamin B5, which is converted into vitamin B5 in the body, and inhibits the activity of cyclooxygenase that metabolizes prostaglandin and lukotriene, which are inflammatory mediators, thereby reducing itching. It prevents or imparts moisture to the skin mucosa. In addition, it promotes cell growth, functions to maintain skin moisture, provides gloss to the skin mucous membrane, and has an effect of preventing skin aging such as wrinkles, elasticity, and melasma.
상기 판테놀은 전체 니오좀 총 중량에 대하여 0.001 내지 10 중량%, 더욱 바람직하게는 3 내지 5 중량% 포함하는 것이 바람직하다. 판테놀의 담지량이 상기 범위 미만인 경우 상술한 가려움 방지, 보습, 피부노화 예방과 같은 효과가 미비하며, 상기 범위를 초과하는 경우 판테놀이 알러지의 항원으로 작용하여 피부발진과 같은 부작용이 발생할 수 있으며, 니오좀의 높은 친수성으로 인해 담지 수율 또한 떨어질 수 있다.The panthenol is preferably included in an amount of 0.001 to 10% by weight, more preferably 3 to 5% by weight, based on the total weight of the niosome. If the supported amount of panthenol is less than the above range, the aforementioned effects such as anti-itching, moisturizing, and skin aging prevention are insufficient, and if it exceeds the above range, panthenol may act as an allergen and cause side effects such as skin rash. Due to the high hydrophilicity of the moths, the loading yield may also be reduced.
상기 엑토인(Ectoin, CAS 번호: 96702-03-3) 은 화학식 C6H10N2O2 을 가진, 박테리아에서 자연적으로 발생하는 널리 공지된 유기 화합물이다. 이는 또한 (S)-2-메틸-3,4,5,6-테트라히드로피리미딘-4-카르복실산으로도 지칭된다. 엑토인은 특히 할로모나다세애(Halomonadaceae) 또는 피르미쿠테스(Firmicutes) 속의 다양한 박테리아로부터 당업계에 널리 공지된 기법에 의해 수득 가능하다.Ectoin (CAS number: 96702-03-3) is a well-known organic compound with the chemical formula C6H10N2O2 that occurs naturally in bacteria. It is also referred to as (S)-2-methyl-3,4,5,6-tetrahydropyrimidine-4-carboxylic acid. Ectoin is obtainable by techniques well known in the art, especially from various bacteria of the genus Halomonadaceae or Firmicutes.
상기 엑토인은 피부 세포, 또는 피부 내 단백질의 표면을 감싸 보호 장벽을 형성하는 작용을 하기 때문에 미세 먼지가 침투하는 것을 차단할 수 있다. 구체적으로 엑토인은 주변 물 분자와 결합이 잘 이루어지는 성질을 가져, 엑토인 수분 착물을 형성하게 되고, 형성된 엑토인 수분 착물은 피부 세포, 또는 피부 내 단백질을 둘러쌈에 따라 피부 표면에 보호 장벽이 형성되어 미세먼지의 침투를 차단할 수 있는 것이다.Since the ectoin acts to form a protective barrier by surrounding the surface of skin cells or proteins in the skin, it can block the penetration of fine dust. Specifically, ectoin has the property of bonding well with surrounding water molecules, forming an ectoin water complex, and the formed ectoin water complex surrounds skin cells or proteins in the skin, forming a protective barrier on the skin surface. It is formed to block the penetration of fine dust.
이외에도 엑토인은 주름 형성 및 색소 침착을 일으키는 입자, 또는 자외선(UVA/UVB) 등으로부터 피부가 손상되는 것을 보호하는 기능을 할 수 있어, 피부 노화를 방지하는 효과를 나타낼 수 있다. 또한 엑토인은 염증에 의해 손상된 피부를 진정시키며 가려움을 방지하고 피부 재생 과정을 활성화시키는 기능도 할 수 있어, 피부 상태의 개선 또는 치료(아토피 피부염, 알레르기 피부염, 또는 여드름 치료 등) 효과를 나타낼 수 있다.In addition, ectoin can function to protect the skin from being damaged by particles or ultraviolet rays (UVA/UVB) that cause wrinkle formation and pigmentation, and thus can exhibit an effect of preventing skin aging. Ectoin can also function to soothe the skin damaged by inflammation, prevent itching, and activate the skin regeneration process, thereby improving or treating skin conditions (such as atopic dermatitis, allergic dermatitis, or acne treatment). there is.
상기 엑토인은 전체 니오좀 총 중량에 대하여 0.001 내지 10 중량%, 더욱 바람직하게는 0.1 내지 2 중량% 포함하는 것이 바람직하다. 엑토인의 함량이 상기 범위 미만인 경우 상술한 피부진정 효과, 가려움 억제 효과 등의 제반 효과가 미비하며, 상기 범위를 초과하는 경우 피부의 자극성이 증가하여 알러지 반응을 유도할 수 있다.The ectoin is preferably included in an amount of 0.001 to 10% by weight, more preferably 0.1 to 2% by weight, based on the total weight of the niosome. When the content of ectoin is less than the above range, the above-described skin soothing effect and anti-itching effect are insufficient, and when it exceeds the above range, skin irritation may be increased and an allergic reaction may be induced.
상기 알란토인(Allantoin)은 CAS 번호 97-59-6의 화합물이고, 글라이옥실산(glyoxylic acid)의 유레이드(ureide) 화합물이다. 알란토인은 상수리나무, 컴프리 뿌리와 사탕무 및 밀의 싹과 같은 곳에서 추출하는 천연물질로서, 세포 증식력의 강화 작용, 창상의 수복 촉진 작용, 결막의 진염 작용, 항알레르기 작용 등을 갖는 것이 알려져 있다. 특히 효과적인 피부 보호 활성 성분으로서 피부의 작은 상처나 트러블 치유에 도움을 주며 건강한 피부 세포의 재생을 촉진시키는 역할을 하는 것과 동시에 상술한 판테놀과 엑토인이 유발할 수 있는 알러지의 항원작용을 억제할 수 있다.The allantoin is a compound of CAS number 97-59-6, and is a ureide compound of glyoxylic acid. Allantoin is a natural substance extracted from places such as oak, comfrey root, sugar beet, and wheat sprouts, and is known to have an action of enhancing cell proliferation, an action of promoting wound repair, an anti-inflammatory action of the conjunctiva, and an anti-allergic action. As a particularly effective skin protection active ingredient, it helps heal small wounds or troubles on the skin, promotes the regeneration of healthy skin cells, and at the same time suppresses the allergic antigen action that can be caused by panthenol and ectoin. .
상기 알란토인은 전체 니오좀 총 중량에 대하여 0.001 내지 10 중량%, 더욱 바람직하게는 0.1 내지 1 중량% 포함하는 것이 바람직하다. 알란토인의 함량이 상기 범위 미만인 경우 상술한 피부보습, 세포 증식, 항알러지 작용 효과가 미비하며, 상기 범위 초과인 경우 알란토인 특유의 낮은 용해성으로 인해 담지된 니오좀의 수율이 하락할 수 있다.The allantoin is preferably included in an amount of 0.001 to 10% by weight, more preferably 0.1 to 1% by weight, based on the total weight of the niosome. If the content of allantoin is less than the above range, the above-mentioned skin moisturizing, cell proliferation, and anti-allergic effects are insignificant, and if it exceeds the above range, the yield of supported niosomes may decrease due to the low solubility peculiar to allantoin.
상기 니오좀은 비이온계 계면활성제, 콜레스테롤, 보조유화제 및 안정화제를 포함하여 형성될 수 있다.The niosome may be formed by including a nonionic surfactant, cholesterol, a co-emulsifier and a stabilizer.
상기 비이온성 계면활성제는 친수성-친유성 밸런스(Hydrophilic-lipophilic balance: HLB)가 3 내지 6, 구체적으로 4 내지 6일 수 있으나, 반드시 이에 제한되는 것은 아니고 유화제(emulsifier 또는 emulsifying agent), 보다 구체적으로 수용성 유화제의 성질을 가져 콜레스테롤을 수성 용매에 용해시킬 수 있는 비이온성 계면활성제를 사용할 수 있다.The nonionic surfactant may have a hydrophilic-lipophilic balance (HLB) of 3 to 6, specifically 4 to 6, but is not necessarily limited thereto, and an emulsifier (emulsifier or emulsifying agent), more specifically A nonionic surfactant having the property of a water-soluble emulsifier and capable of dissolving cholesterol in an aqueous solvent can be used.
상기 비이온계 계면활성제로 예를 들면 폴리옥시에틸렌 알킬에스테르 및 폴리옥시에틸렌 알킬에테르 계열의 것, 보다 구체적으로 소르비탄모노올레에이트, 소르비탄모노이소스테아레이트, 소르비탄모노라우레이트, 소르비탄모노팔미테이트, 소르비탄모노스테아레이트, 소르비탄세스퀴올레에이트, 소르비탄트리올레에이트, 펜타-2-에틸헥실산디글리세롤소르비탄, 테트라-2-에틸헥실산 디글리세롤소르비탄 등의 소르비탄 지방산 에스테르류 등을 들 수 있으며, 더욱 바람직하게는 소르비탄알킬에스테르, 폴리글리세린 지방산 에스테르 등을 들 수 있다.Examples of the nonionic surfactant include polyoxyethylene alkyl esters and polyoxyethylene alkyl ethers, more specifically sorbitan monooleate, sorbitan monoisostearate, sorbitan monolaurate, sorbitan mono Sorbitan fatty acid esters such as palmitate, sorbitan monostearate, sorbitan sesquioleate, sorbitan trioleate, diglycerol sorbitan penta-2-ethylhexylate, and diglycerol sorbitan tetra-2-ethylhexylate and the like, more preferably sorbitan alkyl esters, polyglycerin fatty acid esters and the like.
상기 비이온계 계면활성제는 전체 니오좀 총 중량에 대하여 4 내지 10 중량%, 더욱 바람직하게는 5 내지 7 중량%를 포함할 수 있다. 비이온계 계면활성제의 첨가량이 상기 범위 미만인 경우 니오좀의 생성이 제대로 이루어지지 않으며, 상기 범위를 초과하는 경우 니오좀의 입자 크기가 지나치게 커져 피부로의 흡수력이 떨어질 수 있다.The nonionic surfactant may include 4 to 10% by weight, more preferably 5 to 7% by weight based on the total weight of niosome. If the amount of the nonionic surfactant is less than the above range, the generation of niosomes is not properly performed, and if the amount exceeds the above range, the particle size of the niosome may become excessively large, resulting in poor absorption into the skin.
본 발명에서 상기 콜레스테롤(cholesterol)은 스테로이드(steroid)의 일종으로 동물세포의 세포막을 구성하는 기본 물질이며, 여러 스테로이드 물질의 전구체이다. 화학식 C27H46O로 표시되며, 물, 산 및 알칼리에는 녹지 않으나, 에테르, 클로로포름 등의 유기 용매에 녹는다. 상기 콜레스테롤은 콜레스테롤의 유도체를 포함한다. 콜레스테롤의 유도체는 예를 들면, 시토스테롤(sitosterol), 에르고스테롤, 스티그마스테롤, 4,22-스티그마스타디엔-3-온, 스티그마스테롤 아세테이트, 라노스테롤, 시클로아르테놀, 또는 이들의 조합일 수 있다. 콜레스테롤은 지질 이중층을 강화하고 투과도를 낮추는 것을 도울 수 있다.In the present invention, the cholesterol (cholesterol) is a kind of steroid (steroid), a basic substance constituting the cell membrane of animal cells, and is a precursor of several steroid substances. It is represented by the chemical formula C27H46O, and is insoluble in water, acids and alkalis, but soluble in organic solvents such as ether and chloroform. The cholesterol includes derivatives of cholesterol. The derivative of cholesterol can be, for example, sitosterol, ergosterol, stigmasterol, 4,22-stigmastadien-3-one, stigmasterol acetate, lanosterol, cycloartenol, or combinations thereof. Cholesterol can help strengthen the lipid bilayer and lower permeability.
본 발명에서 상기 콜레스테롤은 첨가량을 한정하는 것은 아니나, 전체 니오좀 총 중량에 대하여 0.01 내지 10 중량%, 더욱 바람직하게는 0.1 내지 1 중량% 포함하는 것이 바람직하다. 콜레스테롤의 함량이 상기 범위를 벗어나는 경우 니오좀의 형성이 제대로 이루어지지 않을 수 있다.In the present invention, the amount of cholesterol added is not limited, but it is preferable to include 0.01 to 10% by weight, more preferably 0.1 to 1% by weight based on the total weight of the total niosome. If the content of cholesterol is out of the above range, formation of niosome may not be performed properly.
본 발명에서 상기 보조유화제는 상기 계면활성제를 보조하여 용매 내에서 친수성 물질과 소수성 물질이 상분리되지 않고 혼화되도록 하는 물질로서, 종류를 한정하는 것은 아니나 고급 알콜(세틸알콜, 스테아릴알콜, 미리스틸알콜, 베헤닐알콜, 세토스테아릴알콜, 세테아릴알콜), 에스테르유(미리스틴산이소프로필, 옥탄산세틸, 올레산올레일, 아디프산이소부틸, 2-에틸헥산산세틸, 모노이소스테아린산 N-알킬글리콜)이나 레시틴일 수 있으며 바람직하게는 레시틴을 포함하는 것이 좋다.In the present invention, the auxiliary emulsifier is a material that assists the surfactant so that the hydrophilic material and the hydrophobic material are mixed without phase separation in the solvent, but is not limited to the type of higher alcohol (cetyl alcohol, stearyl alcohol, myristyl alcohol) , behenyl alcohol, cetostearyl alcohol, cetearyl alcohol), ester oil (isopropyl myristate, cetyl octanoate, oleyl oleate, isobutyl adipate, 2-ethylhexanoate, cetyl monoisostearate, N -alkyl glycol) or lecithin, preferably containing lecithin.
상기 레시틴은 적절하게 정제될 수 있는, 자연적으로 발생하는 또는 합성 레시틴에 관한 것이다. 적절한 레시틴은 계란 또는 콩으로부터 유도된 레시틴을 포함하지만, 이에 제한되는 것은 아니다. 더욱 적절한 레시틴은 디헥사노일(dihexanoyl)-L-알파-레시틴, 디옥타노일(dioctanoyl)-L-알파-레시틴, 디데카노일(didecanoyl)-L-알파-레시틴, 디도데카노일(didodecanoyl)-L-알파-레시틴, 디테트라데카노일(ditetradecanoyl)-L-알파-레시틴, 디헥사데카노일(dihexadecanoyl)-L-알파-레시틴, 디옥타데카노일(dioctadecanoyl)-L-알파-레시틴, 디올레오일-L-알파-레시틴, 디린올레오일-L-알파-레시틴, 알파-팔미톨을 포함하지만, 이에 제한되는 것은 아니다. The lecithin refers to naturally occurring or synthetic lecithin that can be suitably purified. Suitable lecithins include, but are not limited to, egg or soy derived lecithin. More suitable lecithins are dihexanoyl-L-alpha-lecithin, dioctanoyl-L-alpha-lecithin, didecanoyl-L-alpha-lecithin, didodecanoyl- L-alpha-lecithin, ditetradecanoyl-L-alpha-lecithin, dihexadecanoyl-L-alpha-lecithin, dioctadecanoyl-L-alpha-lecithin, dioleo yl-L-alpha-lecithin, dilinoleoyl-L-alpha-lecithin, alpha-palmitol.
레시틴은 통상적으로 인산의 콜린 에스테르에 연결된 지방산의 디글리세라이드의 혼합물이고, 분리(isolation)의 방법에 의존하여 다른 양의 다른 화합물들을 함유할 수 있다. 통상적으로, 상업적인 레시틴은 아세톤-불용성 포스파티드(phosphatide)의 혼합물이다. 바람직하게는, 상기 레시틴은 기술 분야에서 잘 알려진 방법을 사용하여, 콩 및 옥수수, 가장 바람직하게는 콩을 포함하는 씨로부터 얻어진다. 콩으로부터 얻어진 레시틴은 본 발명에서 콩 레시틴이라 한다.Lecithin is a mixture of diglycerides of fatty acids, usually linked to choline esters of phosphoric acid, and may contain different amounts of other compounds depending on the method of isolation. Typically, commercial lecithin is a mixture of acetone-insoluble phosphatides. Preferably, the lecithin is obtained from seeds including soybeans and corn, most preferably soybeans, using methods well known in the art. Lecithin obtained from soybean is referred to as soybean lecithin in the present invention.
상기 보조유화제는 전체 니오좀 총 중량에 대하여 1 내지 10 중량% 포함하는 것이 바람직하다. 보조유화제의 함량이 상기 범위 미만인 경우 니오좀의 안정성이 떨어지는 문제가 있으며, 상기 범위를 초과하는 경우 화장료 조성물의 사용감이 나빠지는 문제점이 있다.The auxiliary emulsifier preferably contains 1 to 10% by weight based on the total weight of the total niosome. If the content of the auxiliary emulsifier is less than the above range, there is a problem that the stability of the niosome is lowered, and when it exceeds the above range, there is a problem that the feeling of use of the cosmetic composition is deteriorated.
상기 안정화제는 니오좀 내부의 상을 형성하고 니오좀의 안정화를 위해 첨가하는 것으로, 이외에도 화장료 조성물의 보습력 향상 및 사용감 개선을 돕는 역할을 한다. 이러한 안정제로 예를 들면 베타인, 부틸렌글라이콜, 다가 알콜, 유기산, 유기염류, 당과 단백질의 복합체 및 글리세린, 프로필렌글라이콜, 디프로필렌글라이콜 등을 포함하는 폴리올류로 이루어진 군에서 선택되는 하나 이상을 사용할 수 있으며, 더욱 바람직하게는 1,3-부틸렌글라이콜, 프로필렌글라이콜, 디프로필렌글라이콜, 폴리에틸렌글라이콜 등의 글라이콜류; 1,2-헥산디올 등의 다가 알콜; 글리세린, 디글리세린, 폴리글리세린 등의 글리세롤류; 솔비톨, 만니톨, 당, 전분당, 라쿠치톨 등의 당류; 구아검, 콘드로이틴 유산나트륨, 히알루론산나트륨, 알긴산나트륨, 메틸셀룰로오스, 하이드록시메틸셀룰로오스, 카르복시비닐폴리머, 폴리비닐알콜, 폴리비닐피롤리돈, 알킬화카르복실비닐폴리머, 폴리아크릴산나트륨, 아라비아고무, 카라기난 등의 수용성 고분자; 염화나트륨, 염화마그네슘, 유산나트륨 등의 염류; 등을 포함할 수 있고, 이들 중 글리세린을 포함하는 것이 바람직하다.The stabilizer is added to form a phase inside the niosome and to stabilize the niosome, and in addition, serves to improve the moisturizing power of the cosmetic composition and improve the feeling of use. Examples of such stabilizers include betaine, butylene glycol, polyhydric alcohols, organic acids, organic salts, complexes of sugars and proteins, and polyols including glycerin, propylene glycol, and dipropylene glycol. One or more selected ones may be used, more preferably glycols such as 1,3-butylene glycol, propylene glycol, dipropylene glycol, and polyethylene glycol; polyhydric alcohols such as 1,2-hexanediol; Glycerols, such as glycerol, diglycerol, and polyglycerol; sugars such as sorbitol, mannitol, sugar, starch sugar, and lacuchitol; Guar gum, sodium chondroitin lactate, sodium hyaluronate, sodium alginate, methylcellulose, hydroxymethylcellulose, carboxyvinyl polymer, polyvinyl alcohol, polyvinylpyrrolidone, alkylated carboxylvinyl polymer, sodium polyacrylate, gum arabic, carrageenan water-soluble polymers such as; Salts, such as sodium chloride, magnesium chloride, and sodium lactate; and the like, among which glycerin is preferably included.
상기 안정화제는 전체 니오좀 총 중량에 대하여 20 내지 60 중량% 포함하는 것이 바람직하다. 안정화제의 첨가량이 상기 범위 미만인 경우 니오좀의 내부상 형성이 제대로 이루어지지 않고 니오좀의 안정성이 좋지 않으며, 상기 범위를 초과하는 경우 조성물의 점도가 급격하게 증가하여 사용감이 나빠지는 단점이 있다.The stabilizer is preferably included in an amount of 20 to 60% by weight based on the total weight of the niosome. When the amount of the stabilizer is less than the above range, the formation of the internal phase of niosome is not properly performed and the stability of the niosome is not good.
상기 성분들은 용매에 투입하고 교반하여 완전히 혼화되도록 할 수 있다. 이때 사용되는 용매는 수용성 용매라면 본 발명에서 한정하지 않으며, 에탄올과 같은 저가알콜, 인산완충생리식염수(Phosphate buffered saline: PBS), 생리식염수 또는 물을 포함하는 것이 바람직하다.The components may be added to a solvent and stirred to completely mix them. The solvent used at this time is not limited in the present invention as long as it is a water-soluble solvent, and preferably includes low alcohol such as ethanol, phosphate buffered saline (PBS), physiological saline or water.
상기 용매는 첨가량을 한정하지 않으며, 전체 니오좀 총 100 중량% 중 20 내지 70 중량% 포함하는 것이 좋다. The amount of the solvent added is not limited, and it is preferable to include 20 to 70% by weight based on 100% by weight of the total niosome.
본 발명에서 상기 니오좀은 제조방법을 한정하지 않는다. 일예로 상기 니오좀은 ① 수용성 성분인 판테놀, 엑토인, 알란토인, 안정제, 용매를 70 내지 100℃에서 가온 용해시켜 수상부를 준비하는 단계; ② 유용성 성분인 콜레스테롤, 안정화제를 50 내지 100℃에서 가온 용해시켜 유상부를 준비하는 단계; ③ 안정화제에 비이온성계면활성제 및 보조유화제를 50 내지 80℃에서 가온 용해시켜 유화제부를 준비하는 단계; ④ 상기 수상부와 유상부를 호모믹서(homo mixer)에 투입하고 1,000 내지 5,000 rpm으로 교반한 후, 다시 유화제부를 투입하고 1,000 내지 5,000 rpm으로 교반하여 니오좀을 형성하는 단계; 및 ⑤ 상기 니오좀이 형성된 조성물을 상온(20℃ 내외)으로 냉각시키면서 안정화하는 단계를 포함하여 진행할 수 있다The niosome in the present invention is not limited to the manufacturing method. For example, the niosome is prepared by: ① preparing an aqueous phase by heating and dissolving water-soluble components such as panthenol, ectoin, allantoin, a stabilizer, and a solvent at 70 to 100 ° C; ② preparing an oil phase by heating and dissolving cholesterol and a stabilizer, which are useful components, at 50 to 100 ° C; ③ preparing an emulsifier part by heating and dissolving a nonionic surfactant and a co-emulsifier in a stabilizer at 50 to 80 ° C; ④ Putting the water phase part and the oil phase part into a homo mixer and stirring at 1,000 to 5,000 rpm, then adding the emulsifier part and stirring at 1,000 to 5,000 rpm to form niosomes; and ⑤ stabilizing the niosome-formed composition while cooling it to room temperature (around 20° C.).
이때 상기 니오좀은 조성물의 혼합 시 별도의 기계장치가 아닌 고압유화장치(high pressure homogenizer) 대신 일반적인 호모믹서를 사용하는 것이 바람직하다. 고압유화장치의 경우 내부 압력이나 온도를 일정 범위로 조절하는데 시간과 에너지가 많이 소요되나, 호모믹서의 경우 교반 시 속도와 온도만을 조절해주는 것만으로도 니오좀을 형성할 수 있어 경제적이고 제조시간을 크게 단축할 수 있어 효율성이 뛰어나다.At this time, when mixing the niosome composition, it is preferable to use a general homomixer instead of a high pressure homogenizer, which is not a separate mechanical device. In the case of a high-pressure emulsification device, it takes a lot of time and energy to adjust the internal pressure or temperature within a certain range. It can be shortened significantly, so the efficiency is excellent.
상기와 같이 제조된 니오좀은 평균입경을 한정하는 것은 아니나, 평균입경이 10 내지 200㎚을 만족할 수 있다. 니오좀의 평균입경이 상기 범위 미만인 경우 담지되는 유효성분의 양이 너무 작아 상술한 효과가 제대로 발현되지 않을 수 있으며, 상기 범위를 초과하는 경우 피부 내부로 침투되지 않아 역시 상술한 효과가 제대로 발현되지 않을 수 있다.The niosome prepared as above is not limited in average particle diameter, but may satisfy the average particle diameter of 10 to 200 nm. If the average particle diameter of niosomes is less than the above range, the amount of the active ingredient supported may be too small, so the above-mentioned effects may not be properly expressed. may not be
본 발명은 상기와 같이 유효성분을 담지한 니오좀을 포함하는 피부 개선용 화장료 조성물을 포함할 수 있다. 이때 상기 화장료 조성물은 전체 조성물 100 중량% 중 니오좀을 0.1 내지 10 중량% 포함할 수 있다. 상기 범위에서 상술한 피부진정, 자극완화, 보습성 개선, 피부 침투효과 증진 등의 효과를 극대화할 수 있다.The present invention may include a cosmetic composition for skin improvement containing niosome carrying an active ingredient as described above. At this time, the cosmetic composition may include 0.1 to 10% by weight of niosome based on 100% by weight of the total composition. Within the above range, effects such as skin soothing, irritation relief, moisturizing improvement, skin penetration enhancement, and the like can be maximized.
상기 화장료 조성물은 당업계에서 화장료 조성물로서 공지된 임의의 제형일 수 있으며, 예를 들어 스킨, 에멀젼, 크림, 선크림, 파운데이션, 에센스, 젤, 팩, 마스크팩, 폼클렌저, 바디클렌저, 유연화장수, 아이라이너, 샴푸, 린스, 비누, 정발제, 양모제, 헤어크림, 헤어 스타일링젤, 윤활제, 치약, 에어로졸 및 경피패치로 이루어진 군에서 선택된 어느 하나의 제형일 수 있으나, 본 발명이 이에 제한되는 것은 아니다.The cosmetic composition may be any formulation known as a cosmetic composition in the art, for example, skin, emulsion, cream, sunscreen, foundation, essence, gel, pack, mask pack, foam cleanser, body cleanser, softening lotion, It may be any one formulation selected from the group consisting of eyeliner, shampoo, rinse, soap, hairdressing agent, hair conditioner, hair cream, hair styling gel, lubricant, toothpaste, aerosol, and transdermal patch, but the present invention is not limited thereto. .
상기 화장료 조성물은 상기 제형에 따라 상기 화장료 조성물의 효과를 손상시키지 않는 범위에서 각종 공지의 첨가제를 추가로 포함할 수 있으며, 일 구체예에 따르면 담체, 용매, 계면활성제, 유화제, 경점제, 컨디셔너, 연화제, 피부 보호 성분, 보습제, 증점제, 윤활제, 충전제, 산화방지제, 기타 보존제, 활성 성분, 특히 피부학적으로 활성인 성분 및 향료 등과, 이들의 혼합물을 추가로 함유할 수 있다.The cosmetic composition may further include various known additives within a range that does not impair the effect of the cosmetic composition according to the formulation, and according to one embodiment, a carrier, a solvent, a surfactant, an emulsifier, a thickening agent, a conditioner, It may further contain emollients, skin care ingredients, humectants, thickeners, lubricants, fillers, antioxidants, other preservatives, active ingredients, particularly dermatologically active ingredients and fragrances, and mixtures thereof.
상기 담체로는 동물섬유, 식물섬유, 왁스, 파라핀,전분, 트라가칸트, 셀룰로오스 유도체, 폴리에틸렌글리콜, 실리콘, 벤토나이트, 실리카, 탈크, 산화아연, 락토오스, 실리카, 알루미늄 하이드록사이드, 칼슘 실리케이트, 폴리아미드 파우더, 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌글리콜, 액상 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미세결정 셀룰로오스, 알루미늄 메타하이드록사이드, 벤토나이트, 아가 또는 트라가칸트, 지방족 알코올 설페이트, 지방족 알코올 에테르 설페이트, 설포숙신산 모노에스테르, 이세티오네이트, 이미다졸리늄 유도체, 메틸타우레이트, 사르코시네이트, 지방산 아미드 에테르 설페이트, 알킬아미도베타인, 지방족 알코올, 지방산 글리세라이드, 지방산 디에탄올아미드, 식물성 오일, 리놀린 유도체, 또는 에톡실화 글리세롤 지방산 에스테르 등을 포함할 수 있으나, 이에 한정되는 것은 아니다.Examples of the carrier include animal fibers, vegetable fibers, wax, paraffin, starch, tragacanth, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, zinc oxide, lactose, silica, aluminum hydroxide, calcium silicate, poly Amide powder, water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol, liquid diluent, ethoxylated isostearyl alcohol, Suspending agents such as polyoxyethylene sorbitol esters and polyoxyethylene sorbitan esters, microcrystalline cellulose, aluminum metahydroxide, bentonites, agar or tragacanth, aliphatic alcohol sulfates, aliphatic alcohol ether sulfates, sulfosuccinic acid monoesters, ise Thionates, imidazolinium derivatives, methyl taurates, sarcosinates, fatty acid amide ether sulfates, alkylamidobetaines, fatty alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, linolin derivatives, or ethoxylated It may include glycerol fatty acid ester and the like, but is not limited thereto.
상기 계면활성제로는 알킬 설페이트(예: 나트륨 라우릴 설페이트, 암모늄 라우릴 설페이트, 나트륨 세테아릴 설페이트); 알킬 설포아세테이트(예: 나트륨 라우릴 설포아세테이트); 알킬 에테르 설페이트(예: 나트륨 라우레트 설페이트, 나트륨 트리데세트 설페이트, 나트륨 올레트 설페이트, 암모늄 라우레트 설페이트); 알킬 에테르 설포석시네이트(예: 이나트륨 라우레트 설포석시네이트); 알킬 글리코사이드(예: 데실 글루코사이드, 라우릴 글루코사이드); 알킬 이세티오네이트 양쪽성 화합물(예: 코카미도프로필 베타인, 나트륨 코코암포아세테이트, 나트륨 라우로암포아세테이트, 이나트륨 라우로암포디아세테이트, 이나트륨 코코암포디아세테이트, 나트륨 라우로암 포프리피오네이트, 이나트륨 라우로암포디프로피오네이트, 상기 언급한 양쪽성 화합물의 칼륨 또는 암모늄 염, 카프릴/카프라미도프로필 베타인, 운데실렌아미도프로필 베타인, 라우로미도프로필 베타인) 및 지방 알콜 폴리글리콜 에테르 등을 들 수 있다.Examples of the surfactant include alkyl sulfates (eg, sodium lauryl sulfate, ammonium lauryl sulfate, and sodium cetearyl sulfate); alkyl sulfoacetates (eg sodium lauryl sulfoacetate); alkyl ether sulfates (eg, sodium laureth sulfate, sodium tridecet sulfate, sodium oleth sulfate, ammonium laureth sulfate); alkyl ether sulfosuccinates (eg disodium laureth sulfosuccinate); alkyl glycosides (eg, decyl glucoside, lauryl glucoside); Alkyl isethionate amphoteric compounds (e.g. cocamidopropyl betaine, sodium cocoamphoacetate, sodium lauroamphoacetate, disodium lauroamphodiacetate, disodium cocoamphodiacetate, sodium lauroam porpripionate, disodium lauroamphodipropionate, potassium or ammonium salts of the aforementioned amphoteric compounds, capryl/capramidopropyl betaine, undecyleneamidopropyl betaine, lauromidopropyl betaine) and fatty alcohol poly Glycol ether etc. are mentioned.
상기 유화제로는 지방산의 염(예: 나트륨 스테아레이트 또는 나트륨 팔미테이트, 유기 비누(예: 모노-, 디- 또는 트리에탄올아미놀레에이트), 황화 또는 설폰화 화합물(예: 나트륨 라우릴 설페이트 또는 나트륨 세틸 설포네이트), 사포닌, 라메폰과 같은 음이온성 화합물; 양이온성 화합물(예: 4급 암모늄 염); 비이온성 화합물(예: 지방 알콜, 포화 또는 불포화 지방산과의 지방산 에스테르, 지방산의 폴리옥시에틸렌에스테르 또는 폴리옥시에틸렌에테르, 에틸렌 옥사이드와 프로필렌 옥사이드 또는 프로필렌 글리콜로부터의 중합체), 양쪽성 화합물(예: 포스파티드), 단백질(예: 젤라틴, 카제인, 알킬아미도베타인, 알킬 베타인 및 암포글리시네이트), 알킬 포스페이트, 알킬폴리옥시에틸렌 포스페이트 또는 상응하는 산, 실리콘 유도체(예: 알킬 디메티콘코플리올) 등을 들 수 있다.These emulsifiers include salts of fatty acids, such as sodium stearate or sodium palmitate, organic soaps, such as mono-, di- or triethanolaminolate, sulfurized or sulfonated compounds, such as sodium lauryl sulfate or sodium cetyl. sulfonates), saponins, ramefons; cationic compounds (e.g. quaternary ammonium salts); nonionic compounds (e.g. fatty alcohols, fatty acid esters with saturated or unsaturated fatty acids, polyoxyethylene esters of fatty acids) or polyoxyethylene ethers, polymers from ethylene oxide and propylene oxide or propylene glycol), amphoteric compounds (e.g. phosphatides), proteins (e.g. gelatin, casein, alkylamidobetaines, alkyl betaines and amphoglyces) cinate), alkyl phosphates, alkylpolyoxyethylene phosphates or corresponding acids, silicone derivatives (eg, alkyl dimethicone copolyol), and the like.
상기 경점제로는 지방 알콜 또는 지방산 에스테르와 이들의 혼합물, 예를 들면, 아세틸화 라놀린 알콜, 알루미늄 스테아레이트, 카보머, 세틸 알콜, 글리세릴 올레에이트, 글리세릴 스테아레이트, 글리세릴 스테아레이트(및) PEG 100 스테아레이트, 마그네슘 스테아레이트, 마그네슘 설페이트, 올레산, 스테아르산, 스테아릴 알콜, 미리스틸 미리스테이트, 이소프로필 팔미테이트, 밀납 및 이의 합성 등가물 및 카보머 등을 들 수 있다.Examples of the viscosity agent include fatty alcohols or fatty acid esters and mixtures thereof, such as acetylated lanolin alcohol, aluminum stearate, carbomer, cetyl alcohol, glyceryl oleate, glyceryl stearate, glyceryl stearate (and) PEG 100 stearate, magnesium stearate, magnesium sulfate, oleic acid, stearic acid, stearyl alcohol, myristyl myristate, isopropyl palmitate, beeswax and its synthetic equivalents and carbomers; and the like.
상기 컨디셔너로는 알킬아미도 암모늄락테이트, 세트리모늄 클로라이드 및 디스테아로일에틸 하이드록시에틸모늄 메토설페이트 및 세테아릴 알콜, 세틸 디메티콘, 세틸 리시놀레에이트, 디메티콘, 라우레트-23, 라우레트-4, 폴리데센, 레티닐 팔미테이트, 4급화 단백질 가수분해물, 4급화 셀룰로즈 및 전분 유도체, 아크릴산 또는 메타크릴산이나 염의 4급화 공중합체, 4급화 실리콘 유도체 등을 들 수 있다.The conditioner includes alkylamido ammonium lactate, cetrimonium chloride and distearoylethyl hydroxyethylmonium methosulfate and cetearyl alcohol, cetyl dimethicone, cetyl ricinoleate, dimethicone, laureth-23, laureth-4, polydecene, retinyl palmitate, quaternized protein hydrolysates, quaternized cellulose and starch derivatives, quaternized copolymers of acrylic acid or methacrylic acid or salts, quaternized silicone derivatives, and the like.
상기 연화제로는 세테아릴 이소노나노에이트, 세테아릴 옥타노에이트, 데실 올레에이트, 이소옥틸스테아레이트, 코코 카프릴레이트/카프레이트, 에틸헥실 하이드록시스테아레이트, 에틸헥실 이소노나노에이트, 이소프로필 이소스테아레이트, 이소프로필 미리스테이트, 올레일 올레에이트, 헥실 라우레이트, 파라피눔 리퀴덤, PEG-75 라놀린, PEG-7 글리세릴 코코에이트, 페트롤라툼, 오조케리트 사이클로메티콘, 디메티콘, 디메티콘 코폴리올, 디카프릴릴 에테르, 부티로스페르뭄파르키, 벅서스 키넨시스, 카놀라, 카르나우바 세라, 코페르니시아 세리페라, 오에노테라 비엔니스, 엘래이스 기넨시스, 프루너스 둘시스, 스쿠알란, 제아 메이, 글리신 소야, 헬리안투스 안누스, 라놀린, 경화 피마자유, 수소화 폴리이소부텐, 수크로즈 코코에이트, 스테아록시 디메티콘, 라놀린 알콜, 이소헥사데칸 등을 들 수 있다.Examples of the softening agent include cetearyl isononanoate, cetearyl octanoate, decyl oleate, isooctyl stearate, coco caprylate/caprate, ethylhexyl hydroxystearate, ethylhexyl isononanoate, Isopropyl Isostearate, Isopropyl Myristate, Oleyl Oleate, Hexyl Laurate, Paraffinum Liquidum, PEG-75 Lanolin, PEG-7 Glyceryl Cocoate, Petrolatum, Ozokerite Cyclomethicone, Dimethicone , Dimethicone Copolyol, Dicaprylyl Ether, Butyrospermumparchy, Buxus Chinensis, Canola, Carnauba Sera, Copernicia Serifera, Oenothera Biennis, Elais ginensis, Prunus dulcis, squalane, zea may, glycine soya, helianthus annus, lanolin, hydrogenated castor oil, hydrogenated polyisobutene, sucrose cocoate, stearoxy dimethicone, lanolin alcohol, isohexadecane and the like.
상기 피부 보호용 성분으로는 식물 추출물, 비스아볼롤, 소염제, 우레아, 알란토인, 판테놀 및 판테놀 유도체, 피탄트리올, 비타민 A, E, C, D, 동물 또는 식물 유래의 세라마이드 및 레시틴 등을 들 수 있다.Examples of the skin protection component include plant extracts, bisabolol, anti-inflammatory agents, urea, allantoin, panthenol and panthenol derivatives, phytantriol, vitamins A, E, C, D, animal or plant-derived ceramides and lecithin, and the like. .
상기 보습제로는 부틸렌 글리콜, 세틸 알콜, 디메티콘, 디미리스틸 타르트레이트, 글루코즈 글리세레스-26, 글리세린, 글리세릴 스테아레이트, 가수분해 유단백질, 락트산, 락토즈 및 다른 당, 라우레트-8, 레시틴, 옥톡시 글리세린, PEG-12, PEG-135, PEG-150, PEG-20, PEG-8, 펜틸렌 글리콜, 헥실렌 글리콜, 피탄트리올, 폴리 쿼터늄-39 PPG-20 메틸 글루코즈 에테르, 프로필렌 글리콜, 나트륨 히알루로네이트, 나트륨 락테이트, 나트륨 PCA, 소르비톨, 석시노글리칸, 합성 밀납, 트리-C14-15 알킬 시트레이트, 전분 등을 들 수 있다.Examples of the humectant include butylene glycol, cetyl alcohol, dimethicone, dimyristyl tartrate, glucose glycereth-26, glycerin, glyceryl stearate, hydrolyzed milk protein, lactic acid, lactose and other sugars, laureth-8, Lecithin, Octoxy Glycerin, PEG-12, PEG-135, PEG-150, PEG-20, PEG-8, Pentylene Glycol, Hexylene Glycol, Phytantriol, Polyquaternium-39 PPG-20 Methyl Glucose Ether, propylene glycol, sodium hyaluronate, sodium lactate, sodium PCA, sorbitol, succinoglycan, synthetic beeswax, tri-C14-15 alkyl citrate, starch and the like.
상기 증점제로는 아크릴레이트/스테아레스-20 메타크릴레이트 공중합체, 카보머, 카복시메틸 전분, 세라 알바, 디메티콘/비닐 디메티콘 가교중합체, 프로필렌 글리콜 알기네이트, 하이드록시에틸셀룰로즈, 하이드록시프로필 메틸셀룰로즈, 실리카, 실리카 디메틸 실릴레이트, 크산탄 고무, 수소화 부틸렌/에틸렌/스티렌 공중합체 등을 들 수 있다.Examples of the thickener include acrylate/steareth-20 methacrylate copolymer, carbomer, carboxymethyl starch, sera alba, dimethicone/vinyl dimethicone crosspolymer, propylene glycol alginate, hydroxyethylcellulose, hydroxypropyl methyl cellulose, silica, silica dimethyl silylate, xanthan gum, hydrogenated butylene/ethylene/styrene copolymer, and the like.
상기 윤활제로는 아디프산, 푸마르산과 이의 염, 벤조산과 이의 염, 글리세린 트리아세테이트, 나트륨 또는 마그네슘 라우릴 설페이트, 마그네슘 스테아레이트, 고체 폴리에틸렌글리콜, 폴리비닐피롤리돈, 붕산, 모노-라우레이트 또는 모노-팔미테이트, 미리스틸 알콜, 세틸 알콜, 세틸스테아릴 알콜, 활석, 고급 지방산의 칼슘 또는 마그네슘 염, 고급 지방산의 모노-, 디- 또는 트리글리세리드, 폴리테트라플루오르에틸렌 등을 들 수 있다.The lubricant includes adipic acid, fumaric acid and its salts, benzoic acid and its salts, glycerin triacetate, sodium or magnesium lauryl sulfate, magnesium stearate, solid polyethylene glycol, polyvinylpyrrolidone, boric acid, mono-laurate or mono-palmitate, myristyl alcohol, cetyl alcohol, cetylstearyl alcohol, talc, calcium or magnesium salts of higher fatty acids, mono-, di- or triglycerides of higher fatty acids, polytetrafluoroethylene and the like.
상기 산화방지제로는 설파이트(예: 아황산나트륨), 토코페롤 또는 이의 유도체, 아스코르브산 또는 이의 유도체, 시트르산, 프로필 갈레이트, 키토산 글리콜레이트, 시스테인, N-아세틸 시스테인 + 황산아연, 티오설페이트(예: 티오황산나트륨) 및 폴리페놀 등을 들 수 있다.Examples of the antioxidant include sulfite (e.g. sodium sulfite), tocopherol or a derivative thereof, ascorbic acid or a derivative thereof, citric acid, propyl gallate, chitosan glycolate, cysteine, N-acetyl cysteine + zinc sulfate, thiosulfate (e.g. sodium thiosulfate) and polyphenols.
또한 상기 조성물은 피부의 적용 부위에 따라 다양한 활성 성분을 포함할 수 있다. 이러한 활성 성분의 예를 들면, 항미생물제, 소염제, 식물 추출제, 비스아볼롤, 판테놀, 토코페롤, 자상 방지, 항자극제 또는 비듬방지용 활성제나, 노화 방지제(예: 레티놀 및 멜리비오즈 등)를 추가로 함유할 수 있다. 다른 적합한 활성제는, 예를 들면, 메디카고 오피시날리스(Medicago officinalis), 악티니디아 키넨시스(Actinidia chinensis), 알란토인, 알로에 바르바덴시스(Aloe barbadensis), 아노나 케리몰리아(Anona cherimolia), 안테미스 노빌리스(Anthemis nobilis), 아라키스 히포개아(Arachis hypogaea), 아르니카 몬타나(Arnica Montana), 아베나 사티바(Avena sativa), 베타-카로텐, 비스아볼롤, 보라고 오피시날리스(Borago officinalis), 부틸렌 글리콜, 칼렌둘라 오피시날리스(Calendula officinalis), 카멜리아 시넨시스(Camellia sinensis), 캄포르, 칸디다 봄비콜라(Candida bombicola), 카프릴로일 글리신, 카리카 파파야(Carica papaya), 센타우레아 시아누스(Centaurea cyanus), 세틸피리디늄 클로라이드, 카모밀라 레쿠티타(Chamomilla recutita), 케노포듐 퀴노아(Chenopodium quinoa), 킨코나 숙시루브라(Chinchona succirubra), 콘드루스 크리스푸스(Chondrus crispus), 시트루스 아우란튬 둘시스(Citrus aurantium dulcis), 시트루스 그란디스(Citrus grandis), 시트루스 리모눔(Citrus limonum), 코코스 누시페라(Cocos nucifera), 코페아 아라비카(Coffea Arabica), 크라태구스 모노기나(Crataegus monogina), 쿠쿠미스 멜로(Cucumis melo), 디클로로페닐 이미다졸디옥솔란, 엔테로모르파 콤프레사(Enteromorpha compressa), 에퀴세툼 아르벤제(Equsetum arvense), 에톡시디글리콜, 에틸 판테놀, 파르네솔, 페룰산, 프라가리아 킬로엔시스(Fragaria chiloensis), 겐티아나 루테아(Gentiana lutea), 깅코 빌로바(Ginkgo biloba), 글리세린, 글리세릴 라우레이트, 글리시르히자 글라브라(Glycyrrhiza glabra), 하마멜리스 비르기니아나(Hamamelis virginiana), 헬리오트로핀, 수소화 야자 글리세라이드, 시트레이트, 가수분해 피마자유, 가수분해 밀 단백질, 하이페리쿰 퍼포라툼(Hypericum perforatum), 아이리스 플로렌티나(Iris florentina), 주니페루스 콤무니스(Juniperus communis), 락티스 프로테이눔(Lactis proteinum), 락토즈, 라우소니아 이네르미스(Lawsonia inermis), 리날룰, 리눔 우시타티시뭄(Linum usitatissimum), 리신, 마그네슘 아스파르테이트, 마그니페라 인디카(Magnifera indica), 말바 실베스트리스(Malva sylvestris), 만니톨, 멜 멜라레우카 알테르니폴리아(mel Melaleuca alternifolia), 멘타 피페리타(Mentha piperita), 멘톨, 메틸 락테이트, 미모사 테누이플로라(Mimosa tenuiflora), 님패아 알바(Nymphaea alba), 올라플루르, 오리자 사티바(Oryza sativa), 판테놀, 파라피눔 리퀴둠, PEG-20M, PEG-26 호호바산, PEG-26 호호바 알콜, PEG-35 피마자유, PEG-40 수소화 피마자유, PEG-60 수소화 피마자유, PEG-8 카프릴/카프르산, 페르시아 그라티시마(Persea gratissima), 페트롤라툼, 칼륨 아스파르테이트, 칼륨 소르베이트, 프로필렌 글리콜, 프루누스 아미그달루스 둘시스(Prunus amygdalus dulcis), 프루누스 아르메니아카(Prunus armeniaca), 프루누스 페르시카(Prunus persica), 레티닐 팔미테이트, 리시누스 콤무니스(Ricinus communis), 로사 카니나(Rosa canina), 로즈마리누스 오피시날리스(Rosmarinus officinalis), 루부스 이대우스(Rubus idaeus), 살리실산, 삼부쿠스 니그라(Sambucus nigra), 사르코신, 세레노아 세룰라타(Serenoa serrulata), 시몬드시아 키넨시스(Simmondsia chinensis), 나트륨 카복시메틸 베타글루칸, 나트륨 코코일 아미노산, 나트륨 히알루로네이트, 나트륨 팔미토일 프랄린, 스테아록시트리메틸실란, 스테아릴 알콜, 황화TEA-리시놀레에이트, 활석, 티무스 불가리스(Thymus vulgaris), 틸리아 코르다타(Tilia cordata), 토코페롤, 토코페릴 아세테이트, 트리데세트-9, 트리티쿰 불가레, 티로신, 운데실레노일 글리신, 우레아, 박시늄 미르틸루스(Vaccinium myrtillus), 발린, 산화아연, 황산아연 등을 들 수 있다.In addition, the composition may include various active ingredients depending on the application site of the skin. Examples of such active ingredients include antimicrobial agents, anti-inflammatory agents, plant extracts, bisabolol, panthenol, tocopherol, anti-cut, anti-irritant or anti-dandruff actives, or anti-aging agents such as retinol and melibiose. can contain. Other suitable active agents are, for example, Medicago officinalis, Actinidia chinensis, allantoin, Aloe barbadensis, Anona cherimolia , Anthemis nobilis, Arachis hypogaea, Arnica Montana, Avena sativa, beta-carotene, bisabolol, Borago officinalis officinalis), butylene glycol, Calendula officinalis, Camellia sinensis, camphor, Candida bombicola, capryloyl glycine, Carica papaya, Centaurea cyanus, cetylpyridinium chloride, Chamomilla recutita, Chenopodium quinoa, Chinchona succirubra, Chondrus crispus), Citrus aurantium dulcis, Citrus grandis, Citrus limonum, Cocos nucifera, Coffea Arabica, Crataegus monogina, Cucumis melo, dichlorophenyl imidazoledioxolane, Enteromorpha compressa, Equsetum arvense, ethoxydiglycol, ethyl panthenol , farnesol, ferulic acid, Fragaria chiloensis, Gentiana lutea, Ginkgo biloba (Gi nkgo biloba), glycerin, glyceryl laurate, Glycyrrhiza glabra, Hamamelis virginiana, heliotropin, hydrogenated palm glycerides, citrate, hydrolyzed castor oil, hydrolyzed Degraded Wheat Protein, Hypericum perforatum, Iris florentina, Juniperus communis, Lactis proteinum, Lactose, Lausonia Iner Lawsonia inermis, linalool, Linum usitatissimum, lysine, magnesium aspartate, Magnifera indica, Malva sylvestris, mannitol, Mel Melaleuca egg Melaleuca alternifolia, Mentha piperita, menthol, methyl lactate, Mimosa tenuiflora, Nymphaea alba, olaflur, Oryza sativa sativa), Panthenol, Paraffinum Liquidum, PEG-20M, PEG-26 Jojoba Acid, PEG-26 Jojoba Alcohol, PEG-35 Castor Oil, PEG-40 Hydrogenated Castor Oil, PEG-60 Hydrogenated Castor Oil, PEG-8 Car Pril/capric acid, Persea gratissima, petrolatum, potassium aspartate, potassium sorbate, propylene glycol, Prunus amygdalus dulcis, Prunus armeniaca ), Prunus persica, Retinyl Palmitate, Ricinus communis, Rosa canina, Rosmarinus officinalis, Rubus Idaeusidaeus), salicylic acid, Sambucus nigra, sarcosine, Serenoa serrulata, Simmondsia chinensis, sodium carboxymethyl betaglucan, sodium cocoyl amino acid, sodium hyaluronic acid. Ronate, sodium palmitoyl praline, stearoxytrimethylsilane, stearyl alcohol, sulfurized TEA-ricinoleate, talc, Thymus vulgaris, Tilia cordata, tocopherol, tocopheryl acetate, tri and the like.
상기 성분들은 본 발명의 목적을 해치지 않는 범위 내에서 그 첨가량을 자유롭게 조절하여 첨가할 수 있으며, 본 발명이 이에 한정되는 것은 아니다.The above components may be added by freely adjusting the addition amount within a range that does not impair the object of the present invention, but the present invention is not limited thereto.
이하 실시예 및 비교예를 들어 본 발명의 바람직한 실시 형태를 상세히 설명한다. 다만 하기 실시예들은 본 발명을 더욱 상세히 설명하기 위한 하나의 예시일 뿐, 본 발명이 하기 실시예들에 의해 제한되는 것은 아니다.Preferred embodiments of the present invention will be described in detail with reference to Examples and Comparative Examples below. However, the following examples are only one example for explaining the present invention in more detail, and the present invention is not limited by the following examples.
(실시예 1 내지 5 및 비교예 1 내지 7)(Examples 1 to 5 and Comparative Examples 1 to 7)
판테놀 등의 유효성분을 포함하는 니오좀의 염증 억제 및 피부 자극의 개선 효과가 있는지 여부를 확인하기 위해 하기 표 1에 기재된 원료와 함량을 사용하여 다음과 같은 방법으로 니오좀을 제조하였다.In order to determine whether there is an effect of inhibiting inflammation and improving skin irritation of niosomes containing active ingredients such as panthenol, niosomes were prepared by the following method using the raw materials and contents shown in Table 1 below.
먼저 수용성 원료인 판테놀, 엑토인, 알란토인, 안정화제를 용매인 정제수에 혼합하고 80℃에서 용해시켜 수상부를 준비하였다. 이와는 별개로 유용성 성분인 콜레스테롤을 안정화제인 폴리올류에 혼합하고 80℃에서 용해시켜 유상부를 준비하고, 비이온계 계면활성제로 소르비탄모노라우레이트 및 폴리글리세린 지방산 에스테르(MITSUBISHI-KAGAKU FOODS CORPORATION 제조)를 1 : 1 중량비로 혼합한 것과 보조유화제인 레시틴을 폴리올류에 70℃에서 용해시켜 유화제부를 준비하였다. 이때 각 성분은 하기 표 1의 기재된 중량%로 혼합하였다. First, water-soluble raw materials such as panthenol, ectoin, allantoin, and a stabilizer were mixed with purified water as a solvent and dissolved at 80° C. to prepare an aqueous phase. Separately, cholesterol, which is an oil-soluble component, is mixed with polyols, which are stabilizers, and dissolved at 80° C. to prepare the oil phase. An emulsifier part was prepared by dissolving the mixed mixture in a weight ratio of 1: 1 and lecithin as an auxiliary emulsifier in polyols at 70 ° C. At this time, each component was mixed in the weight % described in Table 1 below.
그리고 준비된 수상부와 유상부를 호모믹서에 투입하고 3,000rpm으로 교반한 후, 여기에 다시 유화제부를 투입하고 3,000rpm으로 교반하여 유효성분이 담지된 니오좀을 형성하였다. 니오좀이 형성된 후에는 상온에서 냉각시키면서 안정화하였다. 또한 비교예 7은 각 성분들을 상온(25℃)에서 단순 혼합하였다.Then, the prepared water phase part and the oil phase part were put into a homomixer and stirred at 3,000 rpm, and then the emulsifier part was added thereto and stirred at 3,000 rpm to form niosomes loaded with active ingredients. After the formation of niosomes, they were stabilized by cooling at room temperature. In Comparative Example 7, each component was simply mixed at room temperature (25° C.).
[표 1][Table 1]
(실험예 1) - 니오좀의 입도 분석(Experimental Example 1) - Particle size analysis of niosomes
상기 제조된 니오좀 조성물의 입자의 분포와 크기를 조사하기 위해 레이져광산란법(Light scattering, 기기모델; Microtrac S3000, Microtrac Co. Ltd, USA)을 이용하였으며, 1회 스캔 시 30초씩 3회 스캔하여 평균입도를 측정하였다. 또한, 온도에 따른 경시비교를 통한 나노제형의 안정성을 평가하기 위하여 냉온 및 45℃ 보관조건에서 한 달간 보관한 후, 평균입도를 측정하였다.In order to investigate the distribution and size of the particles of the prepared niosome composition, a laser light scattering method (light scattering, instrument model; Microtrac S3000, Microtrac Co. Ltd, USA) was used, and each scan was performed by scanning three times for 30 seconds each. The average particle size was measured. In addition, in order to evaluate the stability of the nanoformulation through time-lapse comparison according to temperature, the average particle size was measured after storage for one month under cold and 45 ° C storage conditions.
[표 2] - 니오좀 조성물의 평균 입자크기(㎚)[Table 2] - Average particle size (nm) of niosome composition
상기 표 2와 같이 니오좀의 입자 크기를 확인한 결과 150㎚ 내외의 나노사이즈로 형성되었으며, 저온 상태에서나 고온 상태에서 니오좀 입자의 안정성이 우수한 것을 알 수 있다. 다만 비교예 7과 같이 유상 성분과 친수성 성분을 단순 혼합한 경우에는 니오좀이 형성되지 않았음을 알 수 있다.As a result of confirming the particle size of the niosome as shown in Table 2, it was formed in a nanosize of about 150 nm, and it can be seen that the stability of the niosome particle is excellent in a low temperature or high temperature state. However, it can be seen that no niosome was formed when the oily component and the hydrophilic component were simply mixed as in Comparative Example 7.
(실험예 2) - 물리적 안정성(Experimental Example 2) - Physical stability
실시예 등의 물리적 안정성을 평가하기 위하여 원심분리(기기모델명; Micro High Speed centrifuge, MICRO 17TR, Hanil, Korea)를 이용하여 10,000 RPM에서 10분씩 1 set로 각각 5회 반복하여 원심분리하고 상분리 또는 침전과 같은 제형의 안정성 변화를 관찰하였다.In order to evaluate the physical stability of the examples, etc., centrifugation (equipment model name; Micro High Speed centrifuge, MICRO 17TR, Hanil, Korea) was used to repeat centrifugation at 10,000 RPM for 10 minutes each 5 times in 1 set, and phase separation or precipitation Changes in the stability of the formulations were observed.
[표 3][Table 3]
(상기 표 3에서 ◎는 양호, ○는 일부 침전 및 오일 분리, ×는 침전 및 확연한 상분리를 뜻한다.)(In Table 3, ◎ means good, ○ means some precipitation and oil separation, and × means precipitation and clear phase separation.)
상기 표 3과 같이 본 발명에 따라 제조된 니오좀은 안정성이 높은 것을 알 수 있다. 다만 실시예 5, 비교예 5와 같이 알란토인의 첨가량이 지나치게 많거나, 비교예 7과 같이 각 성분들을 단순 혼합한 경우 상분리가 심하게 나타난 것을 확인하였다.As shown in Table 3, it can be seen that the niosome prepared according to the present invention has high stability. However, it was confirmed that the phase separation was severe when the amount of allantoin added was too large as in Example 5 or Comparative Example 5 or when the components were simply mixed as in Comparative Example 7.
(실험예 3) - 피부 투과율(Experimental Example 3) - Skin transmittance
Franz glass cell(Standard 직경 9㎜, Receiver 5㎖, Permegear)을 이용하여 피부투과성을 확인하였다. 구체적으로, 상기 Glass cell의 상단과 하단 사이에 실시예 등을 통해 제조된 시편을 각각 50㎎씩 도포한 돼지피부(0.7㎜ 두께, Medikinetics)를 장착하고, 상단과 하단에 각각 500㎕와 5㎖의 TBS(50mM Tris pH 7.5, 150mM NaCl)를 가하였다. 8시간 후 돼지 피부 조직을 파쇄하여 유효성분의 양을 정량 분석하였고, 단위면적당 투과량(㎍/㎠)을 하기 표 4에 기재하였다.Skin permeability was confirmed using a Franz glass cell (Standard diameter 9 mm, Receiver 5 ml, Permegear). Specifically, pig skin (0.7 mm thickness, Medikinetics) to which 50 mg of the specimen prepared in Example was applied was installed between the upper and lower ends of the glass cell, and 500 μl and 5 ml of each were applied to the upper and lower ends of the glass cell, respectively. of TBS (50 mM Tris pH 7.5, 150 mM NaCl) was added. After 8 hours, the pig skin tissue was crushed to quantitatively analyze the amount of active ingredient, and the permeation amount per unit area (μg/cm 2 ) is shown in Table 4 below.
[표 4][Table 4]
상기 표 4와 같이 유효성분을 모두 포함한 실시예 1 내지 5가 비교예들에 비해 월등히 피부 투과성이 향상됨을 알 수 있다. 특히 엑토인이나 알란토인 중 어느 한 성분이 제외된 비교예 1 내지 6은 그렇지 않은 실시예에 비해 피부에 투과되는 성분들이 감소하는 것을 확인할 수 있으며, 니오좀이 형성되지 않은 비교예 7은 유효성분의 투과량이 가장 적은 것을 확인할 수 있다.As shown in Table 4, it can be seen that the skin permeability of Examples 1 to 5 including all active ingredients is significantly improved compared to Comparative Examples. In particular, in Comparative Examples 1 to 6, in which either ectoin or allantoin was excluded, the number of components permeable to the skin was reduced compared to other examples, and in Comparative Example 7, in which no niosome was formed, the active ingredient It can be seen that the penetration amount is the lowest.
(실험예 4) - 항염 관능시험(Experimental Example 4) - Anti-inflammatory sensory test
니오좀의 항염효과를 확인하기 위해 아라키돈산(arachidonic acid)을 이용한 평가법[A. Crummey, G. P. Harper, E. A. Boyle and F. R. Mangan. Inhibition of arachidonic acid-induced ear edema as a model for assessing topical anti-inflammatory compound. Agents and Actions, 1987, 20, p.69~76]을 사용하여 하기와 같이 실시하였다.Evaluation method using arachidonic acid to confirm the anti-inflammatory effect of niosome [A. Crummey, G. P. Harper, E. A. Boyle and F. R. Mangan. Inhibition of arachidonic acid-induced ear edema as a model for assessing topical anti-inflammatory compound. Agents and Actions, 1987, 20, p.69~76] was used as follows.
마우스(hairless mouse)를 시료 당 각 7 마리씩 나누어 양쪽 귀를 시료 적용 전 에탄올로 깨끗이 세척하고 마이크로미터를 이용하여 측정한 후, 실시예 등의 니오좀을 2.0 %를 처리하는 시료군과 인도메타신(indomethacin) 2.0 %를 처리하는 비교군, 그리고 아라키돈산만을 처리하는 대조군으로 나누어 실험을 실시하여 마우스의 귀 두께의 평균치를 측정하였다. 시료군과 인도메타신을 처리하는 비교군은 시료 20 ㎕를, 대조군에는 에탄올 20 ㎕를 1 일 1 회 4 일간 지속적으로 도포하였다. 마지막으로 도포하고 1 시간이 경과한 후에, 좌측에는 에탄올을, 우측귀에는 아라키돈산을 2 ㎎/ear 도포하였고, 도포 1 시간 후 귀의 부종(eaema) 정도를 마이크로미터를 이용하여 양쪽 귀에 대하여 3 회씩 반복 측정하였다. 처리군의 좌측귀는 시료 자체에 의한 염증 유발 정도를 알아보기 위한 대조군으로 이용하였다. 항염효과는 아라키돈산만을 처리한 대조군을 기준으로 부종억제 정도로 판정하고, 그 결과를 표 5에 기재하였다.After dividing hairless mice into 7 mice per sample, both ears were washed thoroughly with ethanol before sample application, measured using a micrometer, and a sample group treated with 2.0% of niosome and indomethacin in Examples and the like. (Indomethacin) 2.0% treated control group, and arachidonic acid only treated control group, the experiment was conducted to measure the average value of the thickness of the ears of the mice. 20 μl of the sample was applied to the sample group and the control group treated with indomethacin, and 20 μl of ethanol was continuously applied to the control group once a day for 4 days. After 1 hour from the last application, ethanol was applied to the left ear and 2 mg/ear of arachidonic acid was applied to the right ear, and 1 hour after application, the degree of eaema of the ear was measured using a micrometer for both ears 3 times each. repeated measurements. The left ear of the treated group was used as a control group to determine the degree of inflammation caused by the sample itself. The anti-inflammatory effect was determined by the degree of edema inhibition based on the control group treated only with arachidonic acid, and the results are shown in Table 5.
[표 5][Table 5]
(억제율(%) = (A - B) / A ×100(Inhibition rate (%) = (A - B) / A × 100
A : 대조군 귀의 평균 두께 변화(아라키돈산 처리 귀의 두께 - 비처리 귀의 두께)A: Change in mean thickness of control ears (thickness of ears treated with arachidonic acid - thickness of ears not treated)
B : 시료 도포군의 귀의 평균 두께 변화(시료 처리 귀의 두께 - 비처리 귀의 두께)B: Change in average thickness of the ear of the sample application group (thickness of the sample treated ear - thickness of the non-treated ear)
상기 표 5와 같이 본 발명에 따라 제조된 니오좀은 최대 43.3%의 높은 염증 억제율을 나타내는 것을 확인할 수 있다. 이러한 억제율 수치는 의약품 성분으로서 항염 효과가 매우 우수한 물질인 인도메타신 대비 약 80 % 정도의 우수한 항염효과를 나타내는 것이다. 다만 실시예 2 내지 5에서와 같이 엑토인과 알란토인의 함량이 일정 이상 벗어나는 경우에는 염증 억제율이 감소하는 것을 확인하였다. 이는 엑토인과 알란토인의 적은 함량에 의해 판테놀의 알러지 항원 유발이 발생하거나, 엑토인과 알란토인이 과다 첨가되어 알러지 항원으로 작용하는 것으로 보인다.As shown in Table 5, it can be seen that the niosome prepared according to the present invention exhibits a high inflammation inhibition rate of up to 43.3%. This inhibition rate value indicates an excellent anti-inflammatory effect of about 80% compared to indomethacin, which is a substance with excellent anti-inflammatory effect as a pharmaceutical ingredient. However, as in Examples 2 to 5, when the contents of ectoin and allantoin deviated from a certain level or more, it was confirmed that the inflammation inhibition rate decreased. It seems that panthenol induces allergens due to a small content of ectoin and allantoin, or that ectoin and allantoin are added excessively to act as allergens.
(실험예 5) - 수분 보유능 및 자극감(Experimental Example 5) - Moisture retention and stimulation
먼저 하기 표 6과 같이 화장수를 제조한 후, 화장수의 사용감을 피험자를 대상으로 관능 평가하였다. 피험자는 30세 내지 50세의 성인 여성 20명을 대상으로 세안 후 견본 하나만 사용한 후 사용감을 각각 흡수력, 촉촉함, 끈적임, 영양감, 사용 후 느낌 및 자극감으로 구분한 후 하기 기술된 평가 기준에 따라 평가하여 표 7에 기재하였다.First, after preparing the lotion as shown in Table 6 below, the feeling of use of the lotion was sensory evaluated for the subjects. The subjects were 20 adult women between the ages of 30 and 50 who used only one swatch after washing their face, and then classified the feeling of use into absorption, moistness, stickiness, nutrition, feeling after use, and irritation, and then evaluated according to the evaluation criteria described below. It is listed in Table 7.
[표 6][Table 6]
(평가기준)(Evaluation standard)
5 : 매우 좋음5: very good
4 : 좋음4 : good
3 : 보통3 : Normal
2 : 나쁨2: bad
1 : 매우 나쁨1 : very bad
[표 7][Table 7]
상기 표 7과 같이 본 발명에 따라 제조된 화장수는 흡수력, 촉촉함, 끈적임, 영양감, 사용 후 느낌 및 자극감 등 여러 평가 부분에서 전체적인 만족도가 매우 우수함을 알 수 있다. 다만 알란토인의 첨가량이 과도한 실시예 8, 비교예 10은 알란토인에 의해 니오좀이 제대로 형성되지 않거나 알란토인이 용해되지 않아 사용감이 극히 나빠지는 것을 확인할 수 있다.As shown in Table 7, it can be seen that the lotion prepared according to the present invention has excellent overall satisfaction in various evaluation areas such as absorption, moistness, stickiness, nutrition, feeling after use, and irritation. However, in Example 8 and Comparative Example 10, in which the amount of allantoin added was excessive, it could be confirmed that the niosome was not properly formed by allantoin or the allantoin was not dissolved, so that the feeling of use was extremely deteriorated.
(실험예 6) - 보습효과(Experimental Example 6) - Moisturizing effect
상기 실시예 6 내지 8, 비교예 8 내지 11을 통해 제조된 화장수를 상박을 중심으로 도포하여 1시간이 지난 후, TEWAMETER TM210(C+K electronic GmbH. Germany)를 이용하여 경피수분 손실량 즉, TEWL(Transepidermal Water Loss)값을 시간 변화에 따른 TEWL 값 변화량 △TEWL로 측정하고, CORNEOMETER CM 820 PC(C+K electronic GmbH. Germany)를 이용하여 표피 수분량에 따른 전기전도도를 측정하여 보습효과의 지속성을 측정하였다.After 1 hour of applying the lotion prepared in Examples 6 to 8 and Comparative Examples 8 to 11 centering on the upper arm, the amount of transepidermal water loss, TEWL, was measured using TEWAMETER TM210 (C+K electronic GmbH. Germany). (Transepidermal Water Loss) value was measured as △TEWL, the amount of change in TEWL value over time, and electrical conductivity according to the amount of epidermal moisture was measured using CORNEOMETER CM 820 PC (C+K electronic GmbH. Germany) to determine the sustainability of the moisturizing effect. measured.
[표 8][Table 8]
[표 9][Table 9]
상기 표 8 및 9와 같이 실시예 6의 △TEWL 값은 비교예들에 비해 경피수분손실량이 개선된 효과를 보였다. 아울러 피부의 수분량을 측정한 Corneometer Value에서도 실시예 6이 다른 비교예들에 비해 최대 30% 이상 증가하여 피부가 매우 촉촉해짐을 알 수 있다. 이는 니오좀을 함유한 실시예 6의 화장수는 시간의 경과에 따라 니오좀이 다른 실시예, 비교예들에 비해 유효성분의 함량이 적절한 이유로 피부에 보다 용이하게 침투함에 따라 보습효과의 지속성을 증대시키기 때문이다.As shown in Tables 8 and 9, the ΔTEWL value of Example 6 showed an improved effect on transepidermal water loss compared to Comparative Examples. In addition, in the Corneometer Value, which measures the moisture content of the skin, it can be seen that Example 6 increases by up to 30% or more compared to other comparative examples, so that the skin becomes very moist. This is because the lotion of Example 6 containing niosomes more easily penetrates the skin over time than other examples and comparative examples because the content of active ingredients is appropriate, thereby increasing the durability of the moisturizing effect. because it makes
이상에서 본 발명의 바람직한 실시예에 대하여 상세하게 설명하였지만 본 발명의 권리범위는 이에 한정되는 것은 아니고 다음의 청구범위에서 정의하고 있는 본 발명의 기본 개념을 이용한 당업자의 여러 변형 및 개량 형태 또한 본 발명의 권리범위에 속하는 것이다.Although the preferred embodiments of the present invention have been described in detail above, the scope of the present invention is not limited thereto, and various modifications and improvements of those skilled in the art using the basic concept of the present invention defined in the following claims are also made according to the present invention. falls within the scope of the rights of
Claims (6)
Including panthenol, ectoin and allantoin loaded therein, characterized in that it contains 3 to 5% by weight of panthenol, 0.1 to 2% by weight of ectoin and 0.1 to 1% by weight of allantoin based on the total weight of the niosome A cosmetic composition for skin improvement comprising panthenol and niosome as active ingredients.
상기 니오좀은 비이온계 계면활성제, 콜레스테롤, 보조유화제 및 안정화제를 포함하여 형성되는 것을 특징으로 하는 판테놀 및 니오좀을 유효성분으로 포함하는 피부 개선용 화장료 조성물.
According to claim 1,
The niosome is a cosmetic composition for skin improvement comprising panthenol and niosome as active ingredients, characterized in that formed by including a nonionic surfactant, cholesterol, a co-emulsifier and a stabilizer.
상기 니오좀은 평균입경이 10 내지 200㎚인 것을 특징으로 하는 판테놀 및 니오좀을 유효성분으로 포함하는 피부 개선용 화장료 조성물.
According to claim 1,
The niosome is a cosmetic composition for skin improvement comprising panthenol and niosome as active ingredients, characterized in that the average particle diameter is 10 to 200 nm.
상기 조성물은 전체 100 중량% 중 니오좀을 0.1 내지 10 중량% 포함하는 것을 특징으로 하는 판테놀 및 니오좀을 유효성분으로 포함하는 피부 개선용 화장료 조성물.
According to claim 1,
The composition is a cosmetic composition for skin improvement comprising panthenol and niosome as active ingredients, characterized in that it contains 0.1 to 10% by weight of niosome out of 100% by weight of the total.
상기 조성물은 스킨, 에멀젼, 크림, 선크림, 파운데이션, 에센스, 젤, 팩, 마스크팩, 폼클렌저, 바디클렌저, 유연화장수, 아이라이너, 샴푸, 린스, 비누, 정발제, 양모제, 헤어크림, 헤어 스타일링젤, 윤활제, 치약, 에어로졸 및 경피패치로 이루어진 군에서 선택된 어느 하나의 제형인 것을 특징으로 하는 판테놀 및 니오좀을 유효성분으로 포함하는 피부 개선용 화장료 조성물.According to claim 1,
The composition is skin, emulsion, cream, sunscreen, foundation, essence, gel, pack, mask pack, foam cleanser, body cleanser, softening lotion, eyeliner, shampoo, conditioner, soap, hairdressing agent, hair conditioner, hair cream, hair styling A cosmetic composition for skin improvement comprising panthenol and niosome as active ingredients, characterized in that it is in any one formulation selected from the group consisting of gel, lubricant, toothpaste, aerosol and transdermal patch.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220112171A KR102516717B1 (en) | 2022-09-05 | 2022-09-05 | A cosmetic composition for improved skin having panthenol and niosome |
CN202311136215.1A CN117122520A (en) | 2022-09-05 | 2023-09-05 | A composition containing panthenol and vesicle as effective components for improving skin |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020220112171A KR102516717B1 (en) | 2022-09-05 | 2022-09-05 | A cosmetic composition for improved skin having panthenol and niosome |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102516717B1 true KR102516717B1 (en) | 2023-03-30 |
Family
ID=85985827
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020220112171A KR102516717B1 (en) | 2022-09-05 | 2022-09-05 | A cosmetic composition for improved skin having panthenol and niosome |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102516717B1 (en) |
CN (1) | CN117122520A (en) |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100628864B1 (en) * | 2004-11-03 | 2006-09-27 | 주식회사 에이블씨엔씨 | Niosome containing vitamins and amaranth oil. and Cosmetic compositions containing the same. |
KR100772336B1 (en) * | 2000-05-19 | 2007-11-01 | 주식회사 코리아나화장품 | Skin care composition containing stabilized Castanea crenata extract and Terminalia chebula extract with niosome |
KR102102578B1 (en) | 2019-06-26 | 2020-04-21 | 코스맥스 주식회사 | Cosmetic composition for strengthening hair bulb comprising mixture of 18β-Glycyrrhetic acid, D-panthenol and Menthol as effective component |
KR102177196B1 (en) * | 2020-02-14 | 2020-11-11 | 주식회사 바이오뷰텍 | Nanoparticle multi-layered lamellar niosomes which is formed by nanoparticlation after being formed large niosomes in a supercritical state and cosmetic composition thereof |
KR20210095352A (en) * | 2020-01-23 | 2021-08-02 | (주)에이티 랩 | Manufacturing method of liposome with enhanced skin permeation |
-
2022
- 2022-09-05 KR KR1020220112171A patent/KR102516717B1/en active IP Right Grant
-
2023
- 2023-09-05 CN CN202311136215.1A patent/CN117122520A/en active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100772336B1 (en) * | 2000-05-19 | 2007-11-01 | 주식회사 코리아나화장품 | Skin care composition containing stabilized Castanea crenata extract and Terminalia chebula extract with niosome |
KR100628864B1 (en) * | 2004-11-03 | 2006-09-27 | 주식회사 에이블씨엔씨 | Niosome containing vitamins and amaranth oil. and Cosmetic compositions containing the same. |
KR102102578B1 (en) | 2019-06-26 | 2020-04-21 | 코스맥스 주식회사 | Cosmetic composition for strengthening hair bulb comprising mixture of 18β-Glycyrrhetic acid, D-panthenol and Menthol as effective component |
KR20210095352A (en) * | 2020-01-23 | 2021-08-02 | (주)에이티 랩 | Manufacturing method of liposome with enhanced skin permeation |
KR102177196B1 (en) * | 2020-02-14 | 2020-11-11 | 주식회사 바이오뷰텍 | Nanoparticle multi-layered lamellar niosomes which is formed by nanoparticlation after being formed large niosomes in a supercritical state and cosmetic composition thereof |
Also Published As
Publication number | Publication date |
---|---|
CN117122520A (en) | 2023-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA3104589A1 (en) | Lactobacillus plantarum for skin care | |
CN111971022B (en) | Use of a composition for preventing or reducing the appearance of signs of inflammation | |
KR101763373B1 (en) | Cosmetic composition comprising plant extracts as effective component | |
KR102026810B1 (en) | A preservative for skin external application, and a cosmetic composition and a pharmaceutical composition comprising the same | |
KR102142311B1 (en) | Skin external composition comprising tangeretin | |
JP4796734B2 (en) | Matrix metalloprotease activity inhibitor | |
KR102217663B1 (en) | Cosmetic Composition For Skin Moisturizing Containing Mixture of Malva Sylvestris (Mallow) Extract, Aloe Barbadensis Leaf Extract, Dioscorea Japonica Root Extract And Hibiscus Esculentus Fruit Extract | |
JP4414495B2 (en) | Antibacterial agent, skin external preparation and skin cleansing agent containing the same | |
EP2100593B1 (en) | Ternary mixtures with increased collagen synthesis | |
KR20110047374A (en) | Cosmetic composition for improving the male skin | |
KR20220051970A (en) | A vitamin composition for cosmetic material encapsulated nano liposome and cosmetic composition using thereof | |
KR101023041B1 (en) | Cosmetic composition for moisturizing effect on the skin | |
JP2011026216A (en) | Cosmetic | |
US20090232915A1 (en) | Mixtures with a collagen synthesis boosting action | |
KR102516717B1 (en) | A cosmetic composition for improved skin having panthenol and niosome | |
KR102283326B1 (en) | Cosmetic compositions containing Fermented products of Lactobacillus, Fermented products of Lactococcus, Sacchromyces peptide, Lactobacillus acidophilus/grape ferment | |
FR3034667A1 (en) | COSMETIC AND / OR DERMATOLOGICAL COMPOSITION AGAINST ACNE | |
KR100531503B1 (en) | Cosmetics compositions comprising natural materials | |
CN115192501A (en) | Cosmetic composition for skin protection comprising extracts of rice, reed, corn silk, malva sylvestris and aloe vera | |
KR100794519B1 (en) | Cosmetic composition comprising bud complex extracts | |
KR101967576B1 (en) | Anti-Atopy, Anti-microbial and Anti-inflammatory Cosmetic Composition Containing a White Rose Extract Stabilized with Lamella Liposome | |
KR101524534B1 (en) | Cosmetic Compositions for Anti-Irritants | |
KR100574233B1 (en) | Cosmetic composition comprising plant extract having moisturizing and anti-irritating activity | |
KR100702891B1 (en) | Cosmetic composition comprising an extract of Lespedeza bicolor having anti-oxidative activity | |
KR100878026B1 (en) | The cosmetic composition for moisturizing of skin containing the thymus quinquecostatus extracts stabilized with nanoliposome |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |